curagen...crgn...911839 - 500 Beiträge pro Seite

[bonDiacomova]

das seit November 1991 bestehende Unternehmen CuraGen Corporation (WKN 911839) forscht ausschließlich im Bereich der „Genomic Technologies".

Man hat sich zum Ziel gesetzt, Medikamente für eine Vielzahl von Erkrankungen auf Basis von „Pharmacogenomics" zu entdecken, entwickeln und zu vermarkten. Um seine Ziele zu erreichen, hat CuraGen mehrere interessante Technologien entwickelt. Die Firma nutze ihre Technologien auch im eigenen Hause. Curagen habe groß angelegte Forschungsprogramme zur Erforschung und Entwicklung neuer Wirkstoffe. Dabei konzentriere sich das Unternehmen auf die Etablierung von Verfahren zur Entwicklung von Produkten, die bei der Behandlung von Stoffwechselerkrankungen, Krebs, Autoimmunerkrankungen sowie Störungen des zentralen Nervensystems Anwendung finden.

Das Unternehmen verkaufe seine „Genomics Technologien" sowie Informationen an pharmazeutische, biotechnologische, landwirtschaftliche Unternehmen sowie an Hersteller von Tierarzneimitteln. Dies geschehe durch Forschungskollaborationen. Zur Zeit bestünden Kooperationen mit Abgenix, Bayer, Biogen, Cor Therapeutics, Genentech, Glaxo-Wellcome, Hoffmann-La Roche, einschließlich Roche Vitamins, sowie Pioneer Hi-Bred International.

Ziel sei es, viel versprechende Wirkstoffkandidaten möglichst schnell auf den Markt zu bringen. Dabei konzentriert sich Curagen auf zwei Klassen von Therapeutika: sezernierte Proteine und vollständige humane monoklonale Antikörper gegen membrangebundene oder sezernierte Proteine.


mkt cap...192 mil $
cash........431 mil $
52 wochen h/t...3,40/25,88 $

saludos...bd

[bonDiacomova]

? bildet curagen einen boden aus ?

[bonDiacomova]

CuraGen Reports Third Quarter 2002 Financial Results


folgend der link zu den zahlen vom 24.10.2002


http://biz.yahoo.com/prnews/021024/nyth046_1.html

[bonDiacomova]

homepage

http://www.curagen.com

u.a. mit news ueber die zusammenarbeit mit bayer

LEVERKUSEN, Germany and NEW HAVEN,
an international, research-based group with major businesses in healthcare, agriculture, polymers and specialty chemicals, and CuraGen Corporation (Nasdaq: CRGN), an integrated genomics-based pharmaceutical company, today announced that CuraGen scientists, in collaboration with Bayer`s toxicologists, have developed an innovative technology capable of predicting a drug compound`s potential for toxicity. The Predictive Toxicogenomics Screen(TM) evaluates drug compound toxicities using very small quantities of compounds that are available immediately after high-throughput drug screening and well in advance of the expensive drug scale-up required for mammalian safety experiments. Utilizing the Predictive Toxicogenomics Screen early in the drug development process, scientists are able to rank-order compounds by their predicted safety profiles. By providing scientists with additional insight into a drug`s toxicity, this pioneering technology is capable of generating information that can potentially save millions of dollars in research and development expenses...

[bonDiacomova]

short interest

http://www.nasdaq.com/asp/quotes_full.asp?mode=&kind=shortin…
=&symbol=&symbol=&symbol=&symbol=&symbol=&FormType=&pathname=&page=short&selected=CRGN" target="_blank" rel="nofollow ugc noopener">http://www.nasdaq.com/asp/quotes_full.asp?mode=&kind=shortin…
=&symbol=&symbol=&symbol=&symbol=&symbol=&FormType=&pathname=&page=short&selected=CRGN

[bonDiacomova]

[bonDiacomova]

[bonDiacomova]

New Technology Identifies Potential Drug Toxicities During Early Research Stages -

NEW HAVEN, Conn., Oct 23, 2002 /PRNewsire-FirstCall via Comtex/ -- CuraGen Corporation (Nasdaq: CRGN), a genomics-based pharmaceutical company, today announced that CuraGen and Ono scientists will evaluate Ono`s drug compounds for potential toxicities by utilizing CuraGen`s Predictive Toxicogenomics Screen(TM) (PTS). CuraGen`s PTS is an innovative technology capable of accurately identifying a drug compound`s potential for toxicity during early-stage research. By evaluating compounds very early in the drug discovery process, Ono scientists will be able to rank-order compounds by their predicted safety profiles and use this information to select the most appropriate drug compounds to advance into further drug development. This marks an expansion of Ono`s existing pharmacogenomics collaboration with CuraGen.
"The application of CuraGen`s Predictive Toxicogenomics Screen is an excellent example of how genomic technologies are impacting drug development today. By shifting compound attrition to the earlier phases of development and improving overall R&D productivity, this technology can provide scientists with information that may be useful in preventing unnecessary drug development expenditures," stated Michael P. McKenna, Ph.D., Vice President of Collaborative Research for CuraGen Corporation.

CuraGen`s industrialized PTS enables inexpensive cellular screening of thousands of compounds annually, and has been used successfully to evaluate more than 150 preclinical drug compounds. Evidence of liver toxicity is one of the primary reasons that drug compounds fail during preclinical development. Nearly 75% of pharmaceutical research and development expenditures are devoted to developing drugs that never reach the market. Detailed information generated by this screen can be used to prioritize compounds based upon their potential for toxicity, or to determine which compounds should be altered through medicinal chemistry to eliminate a potentially toxic effect.

This unique assay was developed by analyzing known toxic compounds and identifying marker genes whose activity correlates with specific modes of liver toxicity. These genes have been subcategorized into marker sets predictive of nine specific liver histopathologies, including cholestasis, necrosis, and hypertrophy, and have been affixed to gene expression microarrays for use in high-throughput comparative analysis. Drug compounds under review are applied in extremely small quantities to primary hepatocyte cells in vitro. The cellular activity of these dosed compounds is then evaluated against the proprietary toxicity markers. The results of this comparison provide scientists with a rank-ordered list of compounds based upon their potential for toxicity, which can be used in determining which compounds have the highest likelihood for successful clinical development.

CuraGen Corporation has been a pioneer in the field of pharmacogenomics, which includes the study of how drugs work, why drugs fail, and which characteristics are indicative of drug toxicity. CuraGen`s expertise stems from pharmacogenomic research conducted with many of the world`s leading pharmaceutical companies in prioritizing portions of their drug pipelines.


saludos...bd

[bonDiacomova]

von der bayer homepage...

Bei CuraGen wird zum Beispiel untersucht,ob ein verdächtiges Gen in Geweben, Zellkulturen oder erkranktem Gewebe aktiv präsent ist.

Nur vier Monate nach Beginn der Zusammenarbeit zwischen Bayer und der amerikanischen CuraGen Corporation sind bereits zwölf Zielproteine identifiziert, die für die Suche nach neuen Arzneimitteln genutzt werden. Im Mittelpunkt der Kooperation mit CuraGen stehen die Therapiefelder Fettsucht und Diabetes. CuraGen gilt als eines der führenden Unternehmen auf dem Gebiet der genomischen Forschung.

[bonDiacomova]

Bayer und die CuraGen Corporation, New Haven, Connecticut (USA), haben zwei in der Kombination bisher einzigartige Vereinbarungen geschlossen. Das erste Abkommen sieht vor, neuartige Medikamente zur Behandlung der Fettsucht und der Zuckerkrankheit bei Erwachsenen nicht nur zu erforschen, sondern auch gemeinsam zu entwickeln und zu vermarkten. Die zweite Vereinbarung beinhaltet, mit speziellen Genomforschungs-Technologien die Substanzen der frühen Pharma-Pipeline von Bayer auf ihre Erfolgsaussichten für eine klinische Weiterentwicklung zu bewerten und damit die Pharma-Forschung und Produktentwicklung bei Bayer noch effektiver zu gestalten.

Mit dem ersten Abkommen über neue Wirkstoffe zur Behandlung der Fettsucht und des Typ-2-Diabetes werden innovative Medikamente entwickelt, die auf der Grundlage von Genanalysen gefunden werden. CuraGen wird im Verlauf der ersten fünf Jahre der Zusammenarbeit 80 Zielproteine (Targets) liefern und Bayer Zugang zu seinen Technologien wie Functional Genomics und Pharmacogenomics gewähren. Bayer bringt u. a. das Ultra-Hochdurchsatz-Suchverfahren, die Pharmakologie und seine Erfahrung in der Entwicklung von Wirkstoffen in die Zusammenarbeit ein. Damit sollen Medikamente gefunden werden, die gegen die von CuraGen gelieferten krankheitsauslösenden Zielproteine wirken. Bayer und CuraGen haben sich zum Ziel gesetzt, zwölf Wirkstoffe zur Behandlung von Fettsucht und Diabetes in die klinische Entwicklung zu bringen. Der damit verbundene Forschungs- und Entwicklungsaufwand von maximal 1,34 Milliarden US-Dollar über 15 Jahre wird im Verhältnis 56 Prozent zu 44 Prozent zwischen Bayer und CuraGen aufgeteilt. Im gleichen Verhältnis werden auch die zu erwartenden Gewinne zugewiesen.

Das zweite Abkommen befasst sich mit den so genannten Pharmacogenomics- und Toxicogenomics-Technologien. Damit können Substanzen aus der Pharma-Pipeline, die sich bei Bayer noch in einer frühen Entwicklungsphase befinden, auf ihre Erfolgsaussichten hin bewertet werden. Dies senkt die Produkt-Entwicklungskosten, reduziert die Zeit bis zur Vermarktung und schafft effektivere Arzneimittel. Das erweiterbare, zunächst über fünf Jahre laufende Abkommen schließt eine Investition von Bayer in Höhe von 124 Millionen US-Dollar ein - 85 Millionen US-Dollar in Form von Aktienbeteiligungen, und Zahlungen an CuraGen in Höhe von 39 Millionen US-Dollar

[bonDiacomova]

bayer´s geschaeftsbericht

unter anlagevermoegen...der Erwerb von Anteilen an der CuraGen Corporation...wirkt sich positiv aus.

in der hoffnung
das sich der erwerb von anteilen der curagen corp.
auch in meinem depot positiv auswirkt...

wuensche ich einen schoenen sonntag...bd

[bonDiacomova]

CuraGen Establishes Collaboration with Mitsubishi in Schizophrenia

NEW HAVEN, Conn., Nov. 5 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN - News), a genomics-based pharmaceutical company, today announced a collaboration with Mitsubishi Pharma Corporation (MPC) in which the companies will leverage CuraGen`s genomics expertise and functional genomic technologies to confirm and characterize drug targets discovered by MPC scientists that have been associated with schizophrenia. Information obtained through this research will better enable MPC scientists to prioritize drug development projects currently underway. In return, CuraGen will receive undisclosed funding and retain ownership of newly discovered potential protein therapeutics, antibody therapeutics and small molecule targets for further development in CuraGen`s existing central nervous system (CNS) drug development program.


"MPC has a strong CNS drug research program that is making significant progress in uncovering new medications to treat schizophrenia. Our scientists have discovered a significant number of novel targets that may prove useful in these drug development efforts. By collaborating with CuraGen, MPC scientists will gain access to bioinformatics, genomics expertise, and a validated system of functional genomic technologies that will aid us in gaining a more comprehensive understanding of our existing drug targets," stated Ken-Ichi Saito, Director of Research Laboratory CNS, Mitsubishi Pharma Corporation.

"This collaboration with MPC will enable scientists from both companies to work together to confirm and better characterize previously discovered targets associated with schizophrenia. Importantly, CuraGen scientists will be able to incorporate new discoveries into its existing CNS drug development program. CuraGen scientists welcome the opportunity to work with MPC scientists in uncovering new information about MPC`s targets that may ultimately enable the development of better treatments for this unmet medical need," stated Christopher K. McLeod, Executive Vice President of CuraGen Corporation.

Contributing to the execution of this agreement was SC Biosciences, which is working as CuraGen`s exclusive agent in Japan.

To date, CuraGen scientists have initiated approximately 200 projects based upon newly discovered drug targets in obesity and diabetes, cancer, inflammation, and CNS disorders. Projects underway at CuraGen include 57 protein projects, of which 5 have been advanced into validated therapeutic candidates; 96 antibody projects, from which 28 fully human monoclonal antibodies are being evaluated in conjunction with Abgenix as potential therapeutics; and 55 small molecule projects, of which 17 screens are in progress or have been completed with Bayer.

[bonDiacomova]

habe eben gewinne realisiert...

durch verkauf des kapital einsatzes...wg kapital erhalt
+ 10 % " verzinsung " wg kapital vermehrung

der "rest" bleibt in form von aktien im depot

"gewinnabsicherung" durch sl bei 3,48 $


einen schoenen tag noch ... bd

[bonDiacomova]

die einschaetzung von stockconsultant zu crgn...

BULLISH Probability - Intermediate trend possibly bullish, excessive downtrend,
unsustainable, trend may turn sideways.
Probability - Mild bullish 3 day chart pattern.


BEARISH Probability - Short term strong rally, rally may start to slow.
Confirmation - at resistance


OVERALL 2 bullish probability and 0 bullish confirmation indicators.
1 bearish probability and 1 bearish confirmation indicators.


OVERALL RATING -2, Hold, short term (1-6 wks)
40%, Bullish 60%, Bearish

[bonDiacomova]

Press Release Source: CuraGen Corporation
CuraGen Refocuses Drug Development Processes
Thursday November 7, 8:55 am ET
Resource Alignment to Strengthen Downstream Drug Development and Reduce Costs


NEW HAVEN, Conn., Nov. 7 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN - News),
a genomics-based pharmaceutical company, announced today a corporate restructuring to reduce early stage research efforts and to focus its resources on prioritizing, selecting and rapidly advancing its most promising drug candidates. As part of this process, the Company is immediately reducing its employee base by approximately 25 percent, or 128 people, and is postponing the construction of a new drug research facility. Charges relating to this corporate restructuring are estimated to be $11 million, including an $8 million charge associated with postponing the building of a new research facility. The objective of this restructuring is to shift drug development resources from discovery-based processes to preclinical and clinical drug development efforts and to decrease overall expenditures.

ADVERTISEMENT
CuraGen remains in a strong financial position, and as of September 30, 2002, CuraGen had available cash and investments of approximately $431 million, including convertible debentures of $150 million due in February 2007. Detailed financial guidance for 2003 will be provided in conjunction with CuraGen`s 2002 year-end financial results, scheduled for release in January 2003.

"CuraGen competed successfully in the race to discover drug targets from the human genome and, through the efforts of a world class team, has emerged with a wealth of knowledge about the molecular basis of disease. We must now focus our resources with greater intensity on drug development projects that are designed to turn these targets, and this knowledge of disease, into cures for unmet medical needs," stated Jonathan M. Rothberg, Ph.D., Founder, Chairman, and CEO of CuraGen Corporation. "Through this restructuring, we anticipate that our cash on hand will be sufficient to fund our operations for four more years. CuraGen remains in a strong financial position and the steps we are taking now are intended to conserve and extend that competitive advantage," added Dr. Rothberg.

To date, CuraGen scientists have initiated approximately 200 projects based upon newly discovered drug targets in obesity and diabetes, cancer, inflammation, and central nervous system (CNS) disorders. Projects underway at CuraGen include 57 protein projects, of which 5 have been advanced into validated therapeutic candidates; 96 antibody projects, from which 28 fully human monoclonal antibodies are being evaluated in conjunction with our partner Abgenix as potential therapeutics; and 55 small molecule projects, of which 17 screens are in progress or have been completed through our partnership with Bayer. CuraGen has filed approximately 400 patent applications covering more than 3,500 pharmaceutically tractable gene transcripts, proteins, and their related utility for treating diseases.

[bonDiacomova]

die kurzform von Business News...

CRGN is changing its focus, leading to a work-force reduction of about 25% and the postponement of a facility`s construction.
In a press release Thursday, Curagen said it wants to work more on prioritizing, selecting and advancing its most promising drug candidates rather than engaging in early-stage research efforts.

With the restructuring, Curagen seeks to shift drug-development resources from discovery-based processes to preclinical and clinical drug development efforts and to decrease overall expenditures. The company anticipates the restructuring will allow it to have sufficient cash on hand to fund operations for four more years.

schoenen tach noch...bd

[bonDiacomova]

Reuters ...CuraGen cuts staff, cites drug-development focus
Thursday November 7, 5:20 am ET

NEW YORK, Nov 7 (Reuters) - Genomics company CuraGen Corp. (NasdaqNM:CRGN - News) on Thursday said it was eliminating 128 jobs -- one-fourth its staff -- and will shift its focus toward developing drugs rather than uncovering causes of disease.

ADVERTISEMENT

"In the past, CuraGen`s efforts have been pretty evenly split between discovery (of biological targets) and attempting to develop drugs ourselves and through our partners," spokesman Mark Vincent said in an interview.

"But in the future, CuraGen will put about 90 percent of its efforts toward developing drugs," Vincent said.

CuraGen, which has identified a myriad of naturally occurring proteins that it believes may be linked to such diseases as obesity, diabetes and cancer, also said it is postponing construction of a new drug research facility.

Besides cutting costs, the company said, the restructuring will shift resources from discovery-based processes to preclinical and clinical drug development efforts.

The restructuring will put the New Haven, Connecticut, company on an altered track -- developing profitable drugs itself rather than concentrating on discovering additional biological targets and then relying on partners to use that information to create medicines.

Charges related to the moves will total $11 million, including $8 million related to the delayed construction, the company said.

CuraGen has forged alliances with two larger companies, Bayer AG (XETRA:BAYG.DE - News) and Abgenix Inc. (NasdaqNM:ABGX - News), which are more experienced and better equipped to develop synthetic compounds and antibodies that interfere with the biological targets the company has identified.

But in such deals, the larger partner typically walks away with the lion`s share of profits from those drugs that finally reach the market.

Meanwhile, CuraGen said its financial condition remains strong, with cash and investments of about $431 million, enough to fund its operations for four more years.

The company said it will provide a detailed 2003 forecast in January, when it releases 2002 year-end financial results.

Last month, CuraGen said its third-quarter loss widened to $19.9 million from $11.1 million a year earlier, in part due to a 22 percent jump in research spending to $21 million.

The company`s shares closed down 7 cents to $4.28 on Thursday, off about 82 percent from the start of the year. They traded as high as $64.85 in late 2000, when investors were snapping up genomics stocks.

But in the past year, investors have dumped shares of biotech companies, especially those like CuraGen, whose pipeline of future drugs may not become reality for years to come.

The American Stock Exchange Biotech Index (AMEX:^BTK - News) is down 38 percent for the year to date

saludos...bd

[bonDiacomova]

CuraGen has jumped on the drug discovery bandwagon. Once a gene researcher, the firm created its GeneScape system featuring four main genetic information databases. Not only does it license GeneScape and provide other R&D service to such companies as GlaxoSmithKline, Genentech, and Monsanto, CuraGen is now developing drugs. With Abgenix it is creating fully human monoclonal antibodies for cancer and cardiovascular and renal diseases. The firm and Bayer (which owns 6% of CuraGen) are developing therapies for diabetes and obesity. The company is seeking partners for its R&D programs for small molecule drugs to treat cancer, central nervous system, inflammatory, and autoimmune diseases.

[bonDiacomova]

Morgan Stanley Research bewertet curagen mit untergewichten

[bonDiacomova]

Institutional Ownership

% Shares Owned: 48.80
% Change in Ownership: -7.84
# Institutions: 95
Total Shares Held: 23,890,494

[bonDiacomova]

etwas allgemeines...

"Ich war noch nie zuvor so pessimistisch"

Dr. Jens Ehrhardt gehört seit langem zu den renommiertesten Börsenexperten Deutschlands. Sein Wort hat in den vergangenen Jahren noch an Bedeutung gewonnen, weil Ehrhardt die Börsen-Baisse richtig voraussagte und sein Fondsmanagement entsprechend ausrichtete. Die von dem Investmentprofi beratenen Fonds (beispielsweise der FMM-Fonds (WKN 847811) und der Astra-Fonds FI (WKN 977700) gehören zu den besten Produkten am Markt. Stock-World sprach mit Jens Ehrhardt über die Aussichten für Aktien.

Stock-World: Herr Dr. Ehrhardt, Sie sind bekannt für Ihre schon langwährende und treffsichere Skepsis in bezug auf die Aussichten für Aktien. Hat sich an dieser Einschätzung nach den starken Kursverlusten in den vergangenen Monaten etwas geändert? Sehen Sie eine Wende?

Dr. Jens Ehrhardt: Da ist grundsätzlich zwischen dem langanhaltenden, übergeordneten Trend und den kurzfristigen Aussichten zu unterscheiden. Auf kurze Sicht ist eine Fortsetzung der im Oktober gestarteten Rallye durchaus vorstellbar.

Stock-World: Aus welchen Gründen?

Dr. Jens Ehrhardt: Mich stimmt vor allem zuversichtlich, dass die Marktteilnehmer derzeit schlechte Nachrichten ignorieren. Der extrem schwache Wert zum Verbrauchervertrauen in den USA oder die enttäuschenden Zahlen von Volkswagen [ WKN: 766400 ] und Deutsche Bank [ WKN: 514000 ] in Deutschland - viel schlimmer können die Meldungen eigentlich gar nicht ausfallen. Und dennoch steigen die Kurse. Das war bei den bisherigen kurzfristigen Kursanstiegen in diesem Jahr nicht der Fall und ist in der Regel ein Hinweis auf die Dynamik eines Aufschwungs. Der DAX hat sich außerdem extrem weit von der 200-Tage-Linie entfernt. Auch die Saisonalität spricht für steigende Kurse, so simpel dieser Indikator auch ist.

Stock-World: Hat diese Einschätzung Auswirkungen auf die Strategie in Ihren Investmentfonds? Normalerweise bevorzugen Sie ja solide Substanzwerte.

Dr. Jens Ehrhardt: Wir haben mit Änderungen in den Fonds reagiert, weil die Substanztitel in einer solchen Marktphase nicht unbedingt zu den Börsenfavoriten gehören. Vor allem Finanzdienstleister sind jetzt höher gewichtet: Aegon [ WKN: 858185 ], Münchener Rück [ WKN: 843002 ], Allianz [ WKN: 840400 ] und AXA [ WKN: 855705 ]. Singulus [ WKN: 723890 ] ist ein weiterer vielversprechender Wert, bei dem wir günstig zum Zuge gekommen sind. Alle offensiven Titel sind aber mit Stopps abgesichert.

Stock-World: Ihr Vertrauen ist nicht groß?

Dr. Jens Ehrhardt: Nein. Im letzten September gaben unsere Indikatoren schon einmal Einstiegssignale. Wir konnten von der Erholung zum Jahresende 2001 gut profitieren. Im Juli 2002 lagen wir mit unserem Timing dagegen falsch. Wir erwarteten wieder eine Erholung und stiegen zu früh ein. Die Stopps bewahrten uns vor höheren Verlusten, aber ungeschoren kamen wir mit unseren Fonds nicht davon. Wir passen sehr gut auf, damit uns das möglichst nicht noch mal passiert.

Stock-World: Das klingt so, als habe Sie das "Missgeschick" im Sommer persönlich getroffen.

Dr. Jens Ehrhardt: Wir sehen es als unsere Aufgabe an, immer das am Aktienmarkt rauszuholen, was möglich ist. Als es im Sommer nicht optimal lief, riefen uns Kunden an und fragten was los sei. Vielleicht waren die Ansprüche dieser Kunden sehr hoch - wir liegen in 2002 nach wie vor deutlich besser als der DAX. Dennoch nehmen meine Kollegen und ich so etwas persönlich.

Stock-World: Dann haben Sie selbst offensichtlich auch sehr hohe Ansprüche an Ihre Leistungen in der Fondsberatung. Schließlich fielen von Juni bis September eigentlich ausnahmslos alle Aktien. Worauf basiert Ihre Einschätzung, Krisen erkennen und umschiffen zu können?

Dr. Jens Ehrhardt: Wir verfügen über sehr viel Börsen-Erfahrung. Ich persönlich bin seit mehr als 30 Jahren im Geschäft und traue mir volkswirtschaftliche Prognosen zu, die den mittel- bis langfristigen Weg abstecken. In den letzten Jahren lag unser Haus in diesem Bereich sehr gut. Daneben haben wir eigene Indikatoren zur Bestimmung des richtigen Timings für den kurzfristigen Anlagehorizont entwickelt. An diesen Indikatoren arbeitet die halbe Firma, und auch auf diesem Gebiet haben wir in der Vergangenheit gute Resultate erzielt. Schließlich ist das Stock-Picking eine erfolgversprechende Methode in schwierigen Märkten. Gerade im Midcap-Bereich haben wir gute Kontakte und finden immer wieder Schnäppchen, bevor der Gesamtmarkt sie entdeckt.

Stock-World: Zum Beispiel?

Dr. Jens Ehrhardt: Bei Vossloh [ WKN: 766710 ] haben wir zuletzt zugegriffen. Das Unternehmen ist hervorragend aufgestellt und günstig bewertet. Die Depfa-Bank [ WKN: 804700 ] ist ein Titel, der bisher auch nur wenig Beachtung findet, obwohl das Geschäft boomt.

Stock-World: Noch einmal zurück zur Ausgangsfrage: Sie sind kurzfristig optimistisch. Wie beurteilen Sie die langfristigen Aussichten für Aktien nach dem Kursrutsch?

Dr. Jens Ehrhardt: Meiner Meinung nach bleibt es bei der Langfristbaisse, möglicherweise noch fünf Jahre oder länger. Dabei halte ich europäische Aktien nicht für hoch bewertet. BASF, Bayer, FMC, MAN - viele Unternehmen notieren analytisch günstig, die DAX-Titel im Schnitt zum Buchwert. Die Bewertung ist nicht das Problem, sondern der Gewinntrend.

Stock-World: Inwiefern Gewinntrend?

Dr. Jens Ehrhardt: Die Kurse pendeln langfristig um den Gewinntrend. Erst bei einer Konjunkturerholung mit signifikant steigenden Erträgen ist auch mit einer Wende an den Börsen zu rechnen. Ich sehe aber keinen Wirtschaftsaufschwung und schon gar keinen steigenden Ergebnistrend. Dem stehen neben dem fehlenden Wachstum auch noch die hohen Verbindlichkeiten im Wege.

Stock-World: Die Unternehmen sind zu hoch verschuldet?

Dr. Jens Ehrhardt: Ja, wird haben zuletzt bei der Betrachtung der DAX-Mitglieder eine Gesamtverschuldung im dreistelligen Milliardenbereich errechnet, ohne die Finanztitel. Ein großer Teil der Gewinne wird durch Zinszahlungen aufgefressen.

Stock-World: Wie sehen Sie unter den Annahmen eines ausbleibenden Aufschwungs in der Wirtschaft und bei den Gewinnen die mittel- bis langfristige Kursentwicklung?

Dr. Jens Ehrhardt: In Europa erwarte ich einen schwierigen Markt, das Abwärtspotenzial ist aber dank der günstigen Bewertung der Unternehmen begrenzt. Es wird immer wieder mal Rallyes geben und anschließend wieder fallende Kurse.

Stock-World: Und in den Vereinigten Staaten?

Dr. Jens Ehrhardt: Das Problem der Verschuldung existiert bei amerikanischen Konzernen gleichfalls. Die Aktien an Wall Street sind noch dazu auch weiterhin zu teuer. Im Durchschnitt notieren die Unternehmen zum dreifachen Buchwert. Das Verhältnis von Kurs zu Cash-Flow - eine aussagekräftigere Kennziffer als das KGV - ist doppelt so hoch wie in Europa. Und wirtschaftlich stehen den Amerikanern unter Umständen noch schwere Zeiten bevor.

Stock-World: Der Double Dip?

Dr. Jens Ehrhardt: Den Double Dip halte ich fast schon für eine optimistische Annahme. Ich glaube an ein noch tiefgreifenderes Abgleiten der Konjunktur als bei der letzten Rezession. Die Bürger der USA sind während einer Krise dem Markt sehr direkt ausgeliefert, sei es bei der Kündigung oder den Sozialleistungen, was sich wiederum auf den Konsum auswirkt. Das stimmt mich sehr skeptisch. Vor allem fehlen Möglichkeiten, gegenzusteuern. Die Fed hat ihr Pulver so gut wie verschossen. Der Staat ist hoch verschuldet und kann kaum noch Impulse geben. Die Bürger sind ebenfalls hoch verschuldet. Woher soll der Schub für Wirtschaftswachstum kommen?

Stock-World: Waren Sie in den über drei Jahrzehnten, die sie sich mit Aktien beschäftigen, jemals zuvor so pessimistisch?

Dr. Jens Ehrhardt: Nein, ich war noch nie zuvor so pessimistisch. In der Vergangenheit hatten wir es immer mit normalen Wirtschaftszyklen zu tun. Jetzt sind Zinsen und Konjunktur gleichzeitig unten. Das ist kein normaler Zyklus und es ist schwer zu sagen, was aus dieser Situation noch folgen wird.

Stock-World: Sie haben als Investmentexperte, Vermögensverwalter und Fondsberater schon sehr viel erreicht. Wenn Sie jetzt noch mehrere schwere Jahre sehen, könnten Sie doch einfach aufhören und sagen: Das tu ich mir nicht mehr an. Wie motivieren Sie sich, in einem solchen Markt weiter zu machen?

Dr. Jens Ehrhardt: Natürlich könnte ich aufhören. Aber es läge nicht in meiner Natur, auszusteigen, wenn es schwierig wird - schon allein wegen der Kunden. Außerdem reizt mich die intellektuelle Aufgabe, Märkte und Kurse zu prognostizieren, auch nach 30 Jahren noch.


wuensche ein schoenes wochenende...saludos...bd

[bonDiacomova]

die einschaetzung von stockconsultant...

BULLISH Probability - Intermediate trend possibly bullish, excessive downtrend,
unsustainable, trend may turn sideways.
Confirmation - at support


BEARISH Confirmation - Strong bearish 3 day chart pattern.


OVERALL 1 bullish probability and 1 bullish confirmation indicators.
0 bearish probability and 1 bearish confirmation indicators.


OVERALL RATING 1, Hold, short term (1-6 wks)
55%, Bullish 45%, Bearish

[bonDiacomova]

bin heute nachmittag wieder rein...sl auf 3,42...saludos...bd

[bonDiacomova]

update von stockconsultant...

BULLISH Probability - Intermediate trend possibly bullish, excessive downtrend,
unsustainable, trend may turn sideways.
Probability - Short term typical pullback, pullback may start to slow.
Confirmation - Strong bullish 3 day chart pattern.


BEARISH None


OVERALL 2 bullish probability and 1 bullish confirmation indicators.
0 bearish probability and 0 bearish confirmation indicators.


OVERALL RATING 8, Strong Outperform, short term (1-6 wks)

90%, Bullish 10%, Bearish

saludos...bd

[bonDiacomova]

[bonDiacomova]

[bonDiacomova]

bei einem kurs von 4.86 $
ein + von 1.02 $... +26.56%

ist das zur zeit die ask seite von curagen...oder auch : shortie zittern ...

4.86 200 Archipelago
4.93 3,200 Island
4.93 1,000 Archipelago
4.94 1,000 Archipelago
4.94 500 Island
4.95 1,000 Archipelago
4.95 500 Island
4.95 1,000 Archipelago
4.96 1,000 Archipelago
4.96 500 Island
4.97 1,000 Archipelago
4.97 500 Island
4.98 1,000 Archipelago
4.98 500 Island
4.99 1,000 Archipelago
4.99 500 Island
5.00 2,000 Island
5.00 1,000

saludos ... bd

[bonDiacomova]

[bonDiacomova]

moin

update stockconsultant...

BULLISH
Probability - Intermediate trend bullish, uptrend starting.
Probability - Mild bullish 3 day chart pattern with Strong accumulation.


BEARISH
Probability - Overbought, odds favor short trades.
Probability - Short term extreme rally, expect rally to pause/stop.
Confirmation - at resistance

OVERALL
2 bullish probability and 0 bullish confirmation indicators.
2 bearish probability and 1 bearish confirmation indicators.

OVERALL RATING -2, Hold, short term (1-6 wks)
40%, Bullish 60%, Bearish


unterstuetzung 4 $ ...ziehe stopploss auf 3,77 $
widerstand 5,0 $... 5,34 $...5,80 $

schoenes wochenende...bd

[bonDiacomova]

shorties wehren sich

ask orders...

5.34 $ 500 Island
5.35 $ 500 Island
5.36 $ 500 Island
5.37 $ 500 Island
5.38 $ 500 Island
5.39 $ 500 Island
5.40 $ 500 Island
5.41 $ 500 Island
5.42 $ 520 Island
5.43 $ 500 Island

[bonDiacomova]

update short interest

SettlementDate... ShortInterest... Avg Daily Share Volume... Days to Cover
Nov. 15, 2002 .......... 1,187,879.................... 319,342...................... 3.72
Oct. 15, 2002 ............ 1,176,209................... 355,221 ......................3.31
Sep. 13, 2002 ............ 1,043,755.................. 288,304...................... 3.62

noch leicht ansteigend ...shorties haben noch nicht aufgegeben

saludos...bd

[bonDiacomova]

moin

hebe stopploss an,
so auf anfang 4,70 $

wuerde mich jedoch wesentlich besser fuehlen,
wenn die fuenf nicht unterschritten wird.

derzeitige mkt. cap. 261 mil $
mittelfristiges kursziel 7,50 $
auf sicht von 1 - 2 jahren 20 $

haengt natuerlich vom gesammten umfeld ab;
wie wohl bei fast jeder aktie.

bon fin de semana...bd

[bonDiacomova]

stopploss auf sk basis unterschritten...

falls sich montag keine gegenreaktion einstellt,
wird der buchgewinn durch verkauf gesichert;
stochastik gibt noch ein wenig anlass zur hoffnung...
aber die stirbt bekanntlich zuletzt

schaun mer mal

schoenes wochenende

saludos...bd

[bonDiacomova]

moin

WASHINGTON (Dow Jones)--CuraGen Corp. said it established a collaborative research agreement with tobacco-products maker Philip Morris Cos. (MO) to "characterize lung response to cigarette smoke using an animal model."
The drug discovery and genomics company said in a filing Wednesday to the Securities and Exchange Commission that the pact began in late November. It`s expected to generate a database of the "cigarette smoke-induced transcriptome of the animal, and to recommend candidate cigarette-smoke-induced genes for further research."

The filing didn`t provide information about the cost of the study or its financing

wuensche einen schoenen tag...bd

[bonDiacomova]

wuensche allen

ein gesundes und erfolgreiches 2oo3



BULLISH
Probability - Intermediate trend bullish, uptrend starting.
Probability - Mild bullish 3 day chart pattern.


BEARISH None


OVERALL
2 bullish probability and 0 bullish confirmation indicators.
0 bearish probability and 0 bearish confirmation indicators.


OVERALL RATING
6, Outperform, short term (1-6 wks)
80%, Bullish 20%, Bearish


saludos...bd

[bonDiacomova]

update short interest

SettlementDate... ShortInterest... Avg Daily Share Volume... Days to Cover
Dec. 13, 2002...........2,041,759 ................388,029.......................5.26
Nov. 15, 2002 ......... 1,187,879..................... 319,342...................... 3.72
Oct. 15, 2002 .......... 1,176,209..................... 355,221 ......................3.31
Sep. 13, 2002 ......... 1,043,755..................... 288,304...................... 3.62

[bonDiacomova]

Companies to Apply Predictive Toxicogenomics and Drug Pathway Mapping Technologies


NEW HAVEN, Conn., Jan. 7 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a genomics-based pharmaceutical company, today announced that CuraGen and Pfizer, Inc (NYSE: PFE) scientists are working together to evaluate compounds under consideration at Pfizer.

CuraGen scientists will apply the Company`s Predictive Toxicogenomics Screen(TM) (PTS) and protein pathway mapping technologies to gain a better understanding of the mechanisms that enable drugs to effectively treat certain diseases. CuraGen`s PTS is applicable in early drug development to evaluate very small quantities of compounds prior to expensive optimization. Scientists hope to use this information to rank-order compounds by their predicted safety profiles, prioritize, and then select the most promising compounds for further development.

CuraGen`s protein pathway mapping technologies can be applied during the later stages of drug development to identify protein pathways associated with drug activity and efficacy. By elucidating these pathways, scientists are able to identify entire families of genes and proteins and evaluate their responses to a specific drug compound. By identifying entire drug pathways, scientists may be able to identify alternative drug targets that may work more appropriately for developing better, safer, and more efficacious drugs.

"Through the application of integrated genomic and proteomic technologies, scientists are able to take a systems biology approach to obtain a more comprehensive understanding of how genes and proteins interact in combination with a specific drug compound. By working closely with Pfizer scientists, we believe that we can identify entire pathways related to drug activity well in advance of clinical trials, thereby enabling the development of more cost effective treatments," stated Christopher K. McLeod, Executive Vice President for CuraGen Corporation.

CuraGen Corporation has been a pioneer in the field of pharmacogenomics, which includes the study of how drugs work, why drugs fail, and which characteristics are indicative of drug toxicity. CuraGen`s expertise stems from pharmacogenomic research conducted with many of the world`s leading pharmaceutical companies in prioritizing portions of their drug pipelines.


saludos...bd

[bonDiacomova]

hola


CuraGen Selects Fully-Human Monoclonal Antibody CR002 as a Candidate for Treating Kidney Disease -

- Abgenix to Manufacture CR002 in its New Antibody Production Facility -


NEW HAVEN, Conn., and FREMONT, Calif.,

CuraGen Corporation (Nasdaq: CRGN - News), a genomics-based pharmaceutical company, and Abgenix, Inc. (Nasdaq: ABGX - News), a biopharmaceutical company focused on antibody therapeutics, today announced new developments in their ongoing antibody discovery and development alliance. CuraGen and Abgenix scientists have successfully developed a fully human monoclonal antibody (CR002) that is being investigated as a treatment for IgA nephropathy, a form of glomerulonephritis (kidney inflammation) that may lead to renal failure and the need for dialysis treatments. CuraGen has selected this antibody drug candidate for development and has the right to develop this candidate across all disease areas. In addition, CuraGen is further exploring the utility of this antibody as a treatment for other forms of glomerulonephritis, including nephritis associated with systemic lupus erythematosus (SLE) and diabetic nephropathy.


folgend der link zur vollstaendigen meldung

http://biz.yahoo.com/prnews/030109/nyth022_1.html

saludos...bd

[bonDiacomova]

bon dia

curagen gibt termin
fuer die veroeffentlichung
der zahlen 2oo2/ausblick 2oo3 bekannt...

conference call at 11 a.m. EST on Thursday, January 30


saludos...bd

[bonDiacomova]

update short interest

SettlementDate... ShortInterest... Avg Daily Share Volume... Days to Cover
Jan. 15, 2003............1,010,691.....................235,146......................4.30
Dec. 13, 2002...........2,041,759 ....................388,029.......................5.26
Nov. 15, 2002 ......... 1,187,879.................... 319,342...................... 3.72
Oct. 15, 2002 .......... 1,176,209.................... 355,221 ......................3.31
Sep. 13, 2002 ......... 1,043,755.................... 288,304...................... 3.62

[bonDiacomova]

hola

Im Falle von Curagen,
dessen Bericht ebenfalls für Donnerstag erwartet wird,
rechnet der Markt mit einer signifikanten Ausweitung des Verlustes.

Für das vierte Quartal werden minus 56 Cent erwartet,
die Spanne der Schätzungen reicht von minus 45 bis minus 78 Cent je Aktie.
Auch die Prognosen für das gesamte Geschäftsjahr 2002 liegen recht weit auseinander:
Bei einer Bandbreite zwischen minus 1,70 und minus 2,04 Dollar je Anteilsschein
ergibt sich ein Mittel von minus 1,81 Dollar.
Der Umsatz wird auf 18 Mio. Dollar geschätzt.

---

daenn schaun mer mal was bei raus kommt

[bonDiacomova]

hola

NEW HAVEN, CuraGen Corporation (Nasdaq: CRGN - News),
today reported financial results for the fourth quarter and fiscal year ended December 31, 2002.

For the year ended December 31, 2002, revenue decreased 22% to 18.2 million $, compared to $23.5 million for the fiscal year 2001, as the Company continued to reduce service-based revenues while increasing focus on its drug pipeline. During the fourth quarter of 2002, revenue decreased 32% to $3.8 million, compared to $5.5 million for the same period in 2001. Research and development expenditures, in support of CuraGen`s pipeline, increased 24% to $81.7 million for the year ended 2002, compared to $65.8 million for the fiscal year 2001. During the fourth quarter of 2002, research and development expenditures decreased 10% to $18.0 million, compared to $20.0 million for the same period in 2001, as a result of corporate restructuring undertaken to decrease early-stage drug discovery expenses.

As of December 31, 2002, CuraGen had available cash and investments of 414.8 million $ and subordinated convertible debt of $150 million.

CuraGen`s net loss for the year ended December 31, 2002, was $90.4 million or $1.85 per share, compared to $42.9 million or $0.89 per share for the fiscal year 2001. The net loss for the fourth quarter of 2002, including an $11.0 million restructuring charge, was $28.9 million or $0.59 per share, compared to a net loss of $16.1 million or $0.33 per share, for the fourth quarter of 2001.


der link zum bericht...

http://biz.yahoo.com/prnews/030130/nyth041_1.html

saludos...bd

[bonDiacomova]

bon dia

die shares sind gestern durch ausgeloestem sl,
mit leider nur noch geringem gewinn,
aus dem depot verschwunden.

saludos...bd

[aufsicht]

CuraGen to Present at the Gerard Klauer Mattison Healthcare Conference

NEW HAVEN, Conn., April 7 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a genomics-based pharmaceutical company, today announced that Jonathan M. Rothberg, Ph.D., Chief Executive Officer, President and Chairman of CuraGen will present at the Gerard Klauer Mattison Healthcare Conference 2003 at 10:30 a.m. EDT on Tuesday, April 8, at Le Parker Meridian in New York, NY.

Dr. Rothberg will provide an overview of the company`s business strategy, technology developments, and drug development pipeline. Specifically, he will discuss:


* CuraGen`s recently filed Investigational New Drug (IND) application to
initiate clinical trials for CG53135, a potential protein therapeutic
being investigated as a treatment for oral mucositis; and

* CR002, a fully human monoclonal antibody being manufactured under a
recently announced agreement with Abgenix, which is being investigated
as a treatment for IgA nephropathy, a form of glomerulonephritis
(kidney inflammation) that may lead to renal failure and the need for
dialysis treatments.

The presentation slides will be available at www.curagen.com.

"Die Praesentation" :

http://216.239.35.120/translate_c?hl=de&u=http://www.curagen…

"...... der Chef kauft" :

http://www.smartmoney.com/eqsnaps/index.cfm?story=insiders&s…

[bonDiacomova]

muy buenas

wuensche frohe ostern

saludos bd


CuraGen to Discuss First Quarter 2003
Financial Results via Conference Call
on April 24, 2003

---> http://biz.yahoo.com/prnews/030417/nyth018_1.html

[bonDiacomova]

hola

May 15, 2003

CURAGEN CORP (CRGN)
Quarterly Report (SEC form 10-Q)

---> http://biz.yahoo.com/e/030515/crgn10-q.html

deseo un

bon fin de semana

saludos bd

[aufsicht]

CuraGen Corporation (ticker: CRGN, exchange: NASDAQ) News Release - 5-Jun-2003


--------------------------------------------------------------------------------
CuraGen to Present at The Needham & Company Second Annual Biotechnology Conference

NEW HAVEN, Conn., June 5 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a genomics-based pharmaceutical company, today announced that Jonathan M. Rothberg, Ph.D., Chief Executive Officer, President and Chairman of CuraGen will present at The Needham & Company Second Annual Biotechnology Conference at 9:00 a.m. EDT on Friday, June 6, at the New York Palace Hotel in New York, NY.

Dr. Rothberg will provide an overview of the Company and review the progress CuraGen is making toward advancing its pipeline of potential protein, antibody, and small molecule therapeutics.

The presentation slides will be available at http://www.curagen.com.

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a genomics-based pharmaceutical company. The Company is applying its industrialized genomic technologies, informatics, and validation technologies to develop a pipeline of protein, antibody, and small molecule therapeutics in the areas of obesity and diabetes, oncology, inflammation, and central nervous system (CNS) disorders. CuraGen`s integrated, functional genomic technologies and Internet-based bioinformatic systems are designed to generate comprehensive information about genes, human genetic variations, gene expression, protein interactions, protein pathways, and potential drugs that affect these pathways. CuraGen`s technology platform and genomics expertise have been used in collaborations with companies including Abgenix, Alexion, Bayer, Biogen, COR Therapeutics, Dupont/Pioneer Hi-Bred International, Gemini Genomics, Genentech, GlaxoSmithKline, Hoffmann-La Roche and its affiliate Roche Vitamins, Mitsubishi, Monsanto, Ono Pharmaceuticals, Pfizer and Sequenom. CuraGen is headquartered in New Haven, CT and additional information is available at http://www.curagen.com.

[bonDiacomova]

moin

[Freudmann]

Curagen heute ganz stark!
Die Charts in #48 informieren Euch aktuell!

MfG

[Freudmann]

[aufsicht]

CuraGen to Present at the Bear Stearns 16th Annual Healthcare Conference

NEW HAVEN, Conn., Sept. 8 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a genomics-based pharmaceutical company, today announced that Jonathan M. Rothberg, Ph.D., the Company`s Chief Executive Officer, President and Chairman, and Timothy M. Shannon, M.D., Senior Vice President of Research and Development and Chief Medical Officer of CuraGen, will present at the Bear Stearns 16th Annual Healthcare Conference at 4:30 p.m. ET on Tuesday, September 9 at The Plaza in New York, NY.

They will provide an overview of the Company and review the progress CuraGen is making towards advancing its broad pipeline of novel products.

The presentation slides will be available at www.curagen.com.

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a genomics-based pharmaceutical company dedicated to improving the lives of patients by developing a broad pipeline of novel protein, antibody, and small molecule therapeutics in the areas of obesity and diabetes, oncology, inflammation, and central nervous system disorders. CuraGen`s therapeutics are based on internally discovered novel genes from the human genome that are believed to play a role in several important mechanisms underlying disease, including peripheral metabolism, cell proliferation, and angiogenesis. CuraGen has established broad development alliances and its experienced preclinical and clinical teams are rapidly advancing the Company`s broad pipeline of novel products. CuraGen`s expertise in genomics and bioinformatics is now being used to help predict efficacy and safety in clinical trials and to prioritize drug candidates with the highest chance of reaching the market. CuraGen`s technology and expertise have been used by more than a dozen leading companies including Bayer, Biogen, Genentech, GlaxoSmithKline, Hoffmann-La Roche and Pfizer. The Company is headquartered in New Haven, CT and additional information is available at www.curagen.com.

http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=CRGN&…

[Freudmann]

Aktuell bei rel.lebhaftem Handel +74c auf 5,69$ (+15%).

[Freudmann]

Stehen uns mit CRGN bald schöne Aussichten bevor?

[Freudmann]

Hallo, gebt 8!

CRGN weiter im Aufwind!
Aktuell 5,91 $ (+5,93%).

Charts in #50 und #48 beachten!

Bleibt der Kurs in etwa so bis zum Schluß, dann wurde
der aus der 1.Dekade Juli stammende Widerstand gebrochen!
Man darf gespannt sein.

MfG

[Freudmann]

Der Tag ging für CRGN weiter mit positiven Kursen.
CRGN gewann 47c auf 6,05 $ (+8,42%)

Der Widerstand von Anfang Juli wurde gebrochen und
mit 6,14 $ ein neues 65-Tage-Hoch erreicht.

[bonDiacomova]

CuraGen Corporation Earnings Conference Call (Q3 2003)

Thu, Oct 23, 2003, 11:00 am Eastern

[bonDiacomova]

moin

Star Analysts...

http://finance.yahoo.com/q/sa?s=crgn

der link zu den zahlen von crgn
http://biz.yahoo.com/prnews/031023/nyth033_1.html

scheun tach

[Preacher]

Hi,
curagen hat sich seit dem letzten beitrag in diesem thread annähernd im Kurs verdoppelt. ganz ohne meldung?
die aktie bleibt wohl weiterhin ein stiefkind im board. nichts spektakuläres. trotzdem konnte man mit curagen nicht nur geld verlieren.
gruß preacher

[bonDiacomova]

moin

CuraGen Corporation Earnings
Conference Call (Q4 2003)Scheduled to start

Thu, Feb 5, 2004, 11:00 am Eastern

scheun tach

[bonDiacomova]

bon dia

NEW HAVEN, Conn., Feb. 5 /PRNewswire-FirstCall/-- CuraGen Corporation (Nasdaq: CRGN - News)
today reported financial results for the fourth quarter and fiscal year ended December 31, 2003.

For the year ended December 31, 2003, CuraGen`s net loss decreased to $74.5 million, including $2.9 million in restructuring charges, or $1.51 per share, compared to $90.4 million including $11.0 million in restructuring charges, or $1.85 per share, for fiscal year 2002. The net loss for the fourth quarter of 2003 decreased to $17.5 million, or $0.35 per share, compared to a net loss of $28.9 million, or $0.59 per share, including an $11.0 million restructuring charge in the fourth quarter of 2002.

Research and development expenditures decreased 21% to $64.5 million for the year ended December 31, 2003, compared to $81.7 million for fiscal year 2002. During the fourth quarter of 2003, research and development expenditures decreased 8% to $16.6 million, compared to $18.0 million for the same period in 2002. Decreased expenditures on early-stage discovery have enabled CuraGen to accommodate increased investments in clinical and preclinical development to support the advancement of the Company`s pipeline of potential therapeutics.

For the year ended December 31, 2003, revenue decreased 62% to $6.9 million, compared to $18.2 million for the fiscal year ended 2002, as the Company continued to reduce service-based revenues while increasing focus on its therapeutic pipeline. During the fourth quarter of 2003, revenue decreased 34% to $2.5 million, compared to $3.8 million for the same period in 2002.

As of December 31, 2003, CuraGen had available cash and investments of $343.6 million, of which 454 Life Sciences` cash and investment balance was $24.2 million. In addition, the Company had subordinated convertible debt of $150 million due in February of 2007.

http://biz.yahoo.com/prnews/040205/neth005_1.html

bon fin de semana

[bonDiacomova]

CuraGen Announces Private Placement of $75 Million of Convertible Subordinated Notes



NEW HAVEN, Conn., Feb. 9 / CuraGen Corporation (Nasdaq: CRGN) today announced that it intends to offer, subject to market and other conditions, $75 million aggregate principal amount of convertible subordinated notes due 2011 in a private placement pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The notes will bear interest, and will be convertible into shares of CuraGen`s common stock at a rate and price to be determined. CuraGen intends to grant the initial purchaser of the notes an option to purchase up to an additional $15 million aggregate principal amount of the notes.

CuraGen intends to use a portion of the net proceeds of this offering to repay its existing debt. Depending on market and other conditions, from time to time, the Company may repurchase a portion of its outstanding 6.00% Convertible Subordinated Debentures in open market purchases, in privately negotiated transactions, or otherwise. In addition, the Company also may use net proceeds for working capital, general corporate purposes and potentially for future acquisitions of complementary businesses or technologies.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities. The offering is being made only to qualified institutional buyers. Any offers of the securities will be made only by means of a confidential offering memorandum. The notes and the common stock issuable upon conversion of the notes have not been registered under the Securities Act or any state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state laws.

[bonDiacomova]

moin

aufgrund der meldung vom 09.02. - siehe # 61
gings mit curagen gen sueden

- gehe von baldiger gegenreaktion aus

- sl knapp unter 6 - ¿ warum nicht ?


mak cap : 315 Mil

As of December 31, 2003, CuraGen had available cash
and investments of $343.6 million,
of which 454 Life Sciences` cash
and investment balance was $24.2 million.
In addition, the Company had subordinated
convertible debt of $150 million due in February of 2007.


NEW HAVEN, Conn., Feb. 10 /PRNewswire-FirstCall

CuraGen Corporation (Nasdaq: CRGN) today announced the pricing of a private placement of $100 million aggregate principal amount of convertible subordinated notes due 2011, bearing an interest rate of 4.00 percent, pursuant to rule 144A under the Securities Act of 1933, as amended. The notes will be convertible into 103.2429 shares of the Company`s common stock for each $1,000 of principal amount of notes representing a conversion price of $9.69 per share of common stock, subject to adjustment in certain circumstances. The initial conversion price represents a premium of 37% relative to the reported last sale price of CuraGen common stock on Nasdaq of $7.07 per share on February 10, 2004. The placement of notes is expected to close on February 17, 2004, subject to customary closing conditions.

[bonDiacomova]

hola

NEW HAVEN, Conn., Feb. 25 /PRNewswire-FirstCall/ -- CuraGen Corporation
(Nasdaq: CRGN) announced today that the U.S. Food and Drug Administration
(FDA) has granted orphan drug designation to CG53135 for the treatment of
radiation induced oral mucositis (OM).

This investigational protein, a novel growth factor discovered by
CuraGen`s integrated platform, promotes epithelial and mesenchymal cell
proliferation in vitro and is active in animal models of OM. CG53135,
CuraGen`s lead product candidate, is currently in Phase I clinical trials to
evaluate the safety and pharmacokinetics in patients with cancer who are at
risk for mucositis. CuraGen expects to initiate Phase II trials with CG53135
in patients with OM in 2004.
" We believe the strength of CG53135 resides in its ability to promote both
epithelial and mesenchymal cell proliferation possibly resulting in increased
activity," stated Timothy Shannon M.D., Chief Medical Officer of CuraGen.
" The FDA`s orphan drug designation further strengthens our program for CG53135
by offering important clinical development and commercialization benefits."
The Orphan Drug Act is intended to encourage companies to develop
therapies for the treatment of diseases that affect fewer than 200,000
individuals in the U.S. at the time of application. Further criteria include
the ability of the product to address an unmet medical need where no approved
treatment option exists or provide significant benefit over available
treatments. Orphan drug designation, granted by the FDA`s Office of Orphan
Products Development, provides CuraGen with a number of potential benefits for
CG53135. Orphan drug designation may result in seven years of market
exclusivity in the United States upon FDA product approval, provided that the
sponsor company continues to meet certain conditions established by the FDA.
Upon marketing authorization and during the period of market exclusivity, the
FDA does not accept or approve other applications to market the same medicinal
product for the same therapeutic indication. Other incentives provided by
orphan designation include protocol assistance and eligibility for research
and development support. Protocol assistance includes regulatory assistance
and reduced filing fees, as well as advice on the conduct of clinical trials.

Background on Oral Mucositis
Oral mucositis is a side effect experienced by cancer patients undergoing
chemotherapy or radiation therapy. The disease is characterized by
inflammation and ulceration of the tissue lining the mouth and throat, leading
to bleeding, pain, and difficulty eating and drinking. Oral mucositis is
sometimes a cause for clinicians to interrupt patients` cancer treatment
regimens, thus limiting the success of therapeutic plans. An effective
treatment for oral mucositis has the potential to treat debilitating symptoms,
to allow cancer patients to tolerate the appropriate doses of cancer
treatment, and to decrease hospitalization time. There is currently no FDA
approved therapy to treat this condition.

[Freudmann]

Um aktuell und schnell informiert zu sein:

[Freudmann]

Nun sage mir einer, CRGN sei nicht sehr volatil! (s.#64)

[Freudmann]

Aussage von #64 gilt unverändert!

Wichtiger aber noch:

Forbes hat sich mit Begründung für
CRGN sehr stark gemacht und auf "strong buy"
erkannt.
Aktie macht seit gestern einen durchaus "erstarkten"
Eindruck!

Gauf!

[bonDiacomova]

CuraGen to Discuss Second Quarter 2004 Financial Results

on July 29, 2004 at 11:00 a.m. Eastern time on Thursday

[bonDiacomova]

CuraGen Corporation (Nasdaq: CRGN - News) today reported financial results for the second quarter ended June 30, 2004. CuraGen continues to advance its downstream drug development efforts while carefully managing overall expenditures. Net loss for the second quarter was $28.2 million or $0.57 per share, compared to $23.4 million or $0.48 per share for the same period in 2003. As of June 30, 2004, CuraGen had available cash and investments of $375.1 million. The Company had outstanding 6% subordinated convertible debt of $130 million due in February 2007 and 4% subordinated convertible debt of $110 million due in February 2011.

http://biz.yahoo.com/prnews/040729/neth015_1.html

[bonDiacomova]

bon domingo

CuraGen Reports Third Quarter 2004

CuraGen had available cash and investments of $351.9 million. The Company had outstanding 6% subordinated convertible debt of $130 million due in February 2007 and 4% subordinated convertible debt of $110 million due in February 2011. The net loss for the third quarter of 2004 included a $1.9 million non-cash asset impairment charge related to the Company`s investment in land being held for the possible future construction of a new protein production facility and corporate headquarters.

http://biz.yahoo.com/prnews/041028/neth004_1.html


CuraGen and Bayer Advance Investigational Compound for Diabetes to Preclinical Phase of Drug Development

http://biz.yahoo.com/prnews/041026/nytu056_1.html

[bonDiacomova]

NEW HAVEN, Conn., Dec. 2 /PRNewswire-FirstCall/ CuraGen Corporation (Nasdaq: CRGN) announced today

it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for CG53135, a novel protein therapeutic being developed for the prevention and treatment of oral mucositis (OM). Under the FDA granted designation CG53135 will be investigated for the prevention of OM in patients receiving hematopoietic stem cell transplantation (HSCT) following myeloablative chemotherapy with or without total body irradiation (TBI).

---> http://biz.yahoo.com/prnews/041202/neth005_1.html

[bonDiacomova]

- Clinical Data Presented at the American Society of Hematology (ASH) 46th Annual Meeting -


NEW HAVEN, Conn., Dec. 4 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) announced today

that results were presented from a Phase I clinical trial with CG53135 for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the ASH 46th Annual Meeting in San Diego, CA. Results from this Phase I study suggest that CG53135 is well tolerated following intravenous administration and support the company`s strategy to investigate in Phase II the safety and efficacy of a single dose of CG53135 for the prevention of oral mucositis.
ADVERTISEMENT


"Oral mucositis is a severe side effect experienced by patients undergoing bone marrow transplants receiving high-dose chemotherapy. A drug with the ability to prevent and treat this condition has the potential to avoid complications associated with OM and improve patients` quality of life," stated Michael W. Schuster, M.D., Principal Investigator, Professor of Clinical Medicine in the Division of Hematology/Oncology at the Weill Medical College of Cornell University, and Director of Stem Cell Transplantation at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. "Based on the results from this Phase I study, I look forward to investigating the efficacy of this molecule in an expanded Phase II clinical trial."

"We are very pleased with the results from this Phase I safety study and look forward to establishing the efficacy of CG53135 for the prevention of oral mucositis in our recently initiated Phase II program," stated William Hahne, M.D., Vice President of Clinical Development. "We are also excited to initiate an additional Phase I program that will evaluate the safety and potential efficacy of CG53135 for the treatment of active OM."

Data available on 22 of the 30 patients dosed to date with CG53135 were presented in a poster entitled, "Phase I Trial of CG53135-05 to Prevent Mucositis in Patients Undergoing High-Dose Chemotherapy (HDCT) and Autologous Hematopoietic Stem Cell Transplantation (AHSCT)." Primary objectives for the study were the evaluation of safety, tolerability, and pharmacokinetics following a single-dose of CG53135. As a secondary objective, the study assessed the development of OM using the WHO oral mucositis assessment scale. Patients received a single-dose of 0.03, 0.1, 0.2, or 0.33 mg/kg CG53135 administered intravenously one day after infusion of blood stem cells following high-dose chemotherapy.

Of the 22 patients (male = 17, female = 5) presented in this poster, median age was 52.5 years (range 25-75) with diagnoses including multiple myeloma (n=11), non-Hodgkin`s lymphoma (n=9), acute myelogenous leukemia (n=1) and desmoplasmic round cell tumor (n=1). High-dose chemotherapy conditioning regimens included high-dose melphalan (Mel 200), carboplatin and thiotepa, cyclophosphamide, carmustine, and etoposide, and busulfan and cyclophosphamide. No drug related serious adverse events were noted following treatment with CG53135. Mild-moderate reactions including nausea, vomiting, tachycardia, hypotension, chills, and fever were observed. Infusional reactions in the two patients treated at the highest dose level were considered dose limiting. A total of 18 of 22 patients (81.8%) did not develop severe grade 3 or 4 OM. Of the 4 patients experiencing severe OM, all were treated with high dose melphalan, and the duration of grade 3 OM was brief (2-5 days) for three of these patients. Two of these patients had a prior history of developing severe OM during previous transplant. One developed brief grade 3 OM, and the other developed Grade 4 OM.

The 0.03, 0.1 and 0.2 mg/kg single doses of CG53135 are being evaluated in a randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial for the prevention of OM in approximately 200 patients receiving HDCT followed by AHSCT.

Reprints of the poster presentation and published abstracts, as well as information about ongoing clinical trials are available on the Company`s website, www.curagen.com, or by emailing [e-mail].

Background on CG53135 and Oral Mucositis (OM)

CG53135, a novel fibroblast growth factor discovered by CuraGen that appears to promote both epithelial and mesenchymal cell proliferation, is currently being investigated for the prevention and treatment of OM, a side effect experienced by cancer patients undergoing chemotherapy or radiation therapy. The disease is characterized by inflammation and ulceration of the tissue lining the mouth and throat, leading to bleeding, pain, and difficulty eating and drinking. OM is sometimes a cause for clinicians to interrupt patients` cancer treatment regimens, thus limiting the success of therapeutic plans. CG53135 is being investigated for the prevention of OM by being administered to patients before the onset of symptoms in order to decrease the incidence and duration of the disease. Animal studies suggest that CG53135 may also be effective for the treatment of OM when it is administered after the onset of early signs of OM in order to decrease the duration and progression to severe OM. An effective therapy for OM has the potential to treat debilitating symptoms, to allow cancer patients to better tolerate the appropriate doses of cancer treatment, and to decrease hospitalization time.

[bonDiacomova]

[bonDiacomova]

BULLISH

Probability - Intermediate trend possibly bullish, Mild uptrend.
Probability - Extreme Oversold, odds definitely favor long trades.
Probability - Short term extreme pullback, expect pullback to pause/stop.
Probability - Strong Down trend (1 month), may start to turn sideways.
Confirmation - at support


BEARISH

Probability - Mild bearish 3 day chart pattern with Good 3 day distribution.
Confirmation - Mild bearish 1 day moneyflow



- CuraGen Corporation (Nasdaq: CRGN) today announced that the Company will be presenting at the Piper Jaffray Healthcare Conference at 3:00 p.m. Eastern time on Tuesday, January 25 at The Pierre Hotel in New York, NY.
Timothy M. Shannon, M.D., Executive Vice President of Research and Development and Chief Medical Officer, will provide an overview of the Company and review the progress CuraGen is making toward advancing its pipeline of protein, antibody, and small molecule therapeutics.

[bonDiacomova]

CuraGen Corporation (Nasdaq: CRGN) today announced

that Company executives will be holding a conference call

to discuss CuraGen`s fourth quarter and year end 2004 financial results

at 11:00 a.m. Eastern Time on Thursday, February 3, 2005.

[bonDiacomova]

CuraGen and TopoTarget Advance PXD101 into Phase II Clinical Program

Tuesday February 1, 6:30 am ET

- First Phase II trial evaluating the role of PXD101 in the treatment of Multiple Myeloma


- CuraGen Corporation (Nasdaq: CRGN) and TopoTarget A/S today announced the initiation of patient dosing in a Phase II clinical trial evaluating PXD101, a small molecule histone deacetylase (HDAC) inhibitor, as a potential treatment for advanced multiple myeloma, a deadly type of blood cancer. The companies reported that initiation of this Phase II trial triggered an undisclosed milestone payment to be made by CuraGen to TopoTarget. CuraGen also announced that they have successfully filed an investigational new drug application (IND) for PXD101 to the Food and Drug Administration, allowing initiation of this trial at clinical sites in the United States.
ADVERTISEMENT


"Based on results obtained in Phase I, we are very pleased to advance PXD101 into Phase II and evaluate it as a potential treatment for multiple myeloma," stated William Hahne, M.D., Vice President of Clinical Development at CuraGen. "Throughout 2005, we expect to initiate additional Phase II trials that will investigate PXD101 as a potential treatment for other types of solid and hematologic cancers, and Phase Ib/II studies to explore the safety and activity of PXD101 in combination with other chemotherapy regimens and newer targeted therapies."

This Phase II clinical trial is an open label, multicenter study evaluating the efficacy and safety of PXD101 administered as a single-agent and in combination with dexamethasone, for the treatment of advanced multiple myeloma in patients who have previously failed at least two treatment regimens. The trial is expected to enroll approximately 50 patients at multiple sites in Europe and the United States. Following enrollment, patients will receive 900 mg/m2/day PXD101 administered intravenously once daily for five consecutive days every three weeks for two cycles. Patients will then be evaluated for tumor response by standard criteria and will either continue receiving up to eight cycles of PXD101 if they demonstrate response or stable disease, or begin combination therapy consisting of PXD101 and dexamethasone. The study is expected to be complete by mid 2006.

"We are pleased with the progress we have made in advancing our pipeline of therapeutics," stated Timothy M. Shannon M.D., Executive Vice President of Research and Development and Chief Medical Officer at CuraGen. "In addition to PXD101 in Phase II; CG53135, a protein therapeutic, is being evaluated in a Phase II clinical trial for the prevention of oral mucositis; CR002, a fully- human monoclonal antibody, is being investigated in Phase I for IgA nephropathy and kidney inflammation, and we have identified two additional potential therapeutics that we expect to enter the clinic in 2006: CR011, an antibody-drug conjugate, being investigated for metastatic melanoma, and CT052, a small molecule compound being co-developed with Bayer Pharmaceuticals for type 2 diabetes."

About Multiple Myeloma

Multiple myeloma (MM) is a progressive cancer arising from a particular type of blood cell, called plasma cells. It is the second most prevalent blood cancer in the U.S. with nearly 50,000 individuals suffering from MM, and more than 15,000 new cases expected to be diagnosed this year. MM is characterized by excessive numbers of abnormal plasma cells in the bone marrow and the overproduction of abnormal immunoglobulins. As a result of MM, patients may develop bone lesions, anemia, elevated blood calcium levels, kidney damage, and a decreased ability to fight off infections. Despite the availability of treatments for MM, there is currently no cure for this disease.

About PXD101

PXD101 is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, and is currently being evaluated in a Phase II clinical trial for the treatment of multiple myeloma. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes, and have been shown to: arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents. In August 2004, CuraGen signed a Clinical Trials Agreement with the National Cancer Institute (NCI) under which the NCI will sponsor several additional clinical trials to investigate PXD101 for the treatment of various cancers, both as a single-agent and in combination chemotherapy regimens.

About TopoTarget

TopoTarget is a British/Danish biopharmaceutical company dedicated to the discovery, development and clinical progression of new and improved therapeutics for the cancer patient. The Company was created by the merger of TopoTarget A/S, the Danish oncology company and Prolifix Ltd, the UK based cell cycle company. TopoTarget develops novel pharmaceuticals and aims to identify and market new indications for existing compounds. It applies its precise and in-depth understanding of the molecular mechanisms of cancer with its wide experience in clinical oncology practice to develop new and effective medicines to combat the disease. TopoTarget is based in Copenhagen, Denmark and Oxford, UK. For more information refer to http://www.topotarget.com.

[bonDiacomova]

kurs 6 $

[bonDiacomova]

CuraGen Reports Fourth Quarter
and Year End 2004 Financial Results
and 2005 Projected Milestones and Financial Guidance


---> http://biz.yahoo.com/prnews/050203/neth011_1.html



Cash and investments 328 mil $

[bonDiacomova]

Income Statement

http://finance.yahoo.com/q/is?s=crgn

[bonDiacomova]

Annual Report

http://biz.yahoo.com/e/050314/crgn10-k.html

[bonDiacomova]

454 Life Sciences Installs First Genome Sequencing System at the Broad Institute

454 GENOME SEQUENCING SYSTEM

Technology allows leading researchers to read genomes up to 100 times faster

BRANFORD, Conn., March 25 /PRNewswire-FirstCall/

454 Life Sciences, a majority-owned subsidiary of CuraGen Corporation (Nasdaq: CRGN), announced today that it has sold and installed its first 454 Genome Sequencing System at the Genome Sequencing and Analysis program of the Broad Institute of MIT and Harvard, a research collaboration of the Massachusetts Institute of Technology, Harvard University and its hospitals and the Whitehead Institute for Biomedical Research. The system, which utilizes novel technology developed by 454 Life Sciences, has the potential to perform sequencing 100 times faster than conventional sequencing machines.

---> http://biz.yahoo.com/prnews/050325/nef002_3.html

[bonDiacomova]

akt kurs 3.84 $

Jonathan Rothberg to Step Down as Chief Executive Officer of CuraGen

- Company initiating search for new CEO --


NEW HAVEN, Conn., April 5 /PRNewswire-FirstCall/ --

CuraGen Corporation (Nasdaq: CRGN) announced today that Jonathan M. Rothberg, Ph.D. has informed the Board of Directors of his intention to step down so that the company can recruit a new Chief Executive Officer. Dr. Rothberg will remain in his current role until the company appoints a new CEO.

"Under Jonathan`s leadership, CuraGen has developed a portfolio of promising therapeutics, strong intellectual property, a solid cash position, as well as the revolutionary technology at 454 Life Sciences," said Robert Patricelli, Lead Director of the CuraGen Board of Directors. "Since founding the Company, he has led CuraGen in its initial public offering in 1998 and was integral in the Company`s efforts to raise over $650 million in capital over 7 years. Jonathan was also successful in recruiting an outstanding, experienced senior management team."

"I am excited to be part of the Company`s search for a new Chief Executive Officer with the experience, track record and commitment to turn our pipeline into drugs," says Dr. Jonathan Rothberg.

Patrick Zenner, a member of the Board of Directors, has been asked to chair the search committee for the new CEO.

[bonDiacomova]

akt kurs 3,07 $


CuraGen Reports First Quarter 2005 Results

http://biz.yahoo.com/prnews/050428/neth008.html?.v=8

[bonDiacomova]

akt kurs 3,53 $

CuraGen Announces Executive Management Changes

NEW HAVEN, Conn., May 12

CuraGen Corporation (Nasdaq: CRGN) today announced changes to its executive management team, including the management of its majority-owned subsidiary 454 Life Sciences Corporation.

In order to take full advantage of the recently announced partnership between 454 Life Sciences and Hoffmann-La Roche, Inc., CuraGen founder and Chief Executive Officer Jonathan M. Rothberg, Ph.D., has accelerated his previously announced decision to step down from active management at CuraGen. Dr. Rothberg will remain on the CuraGen Board of Directors and be Chairman of the Board of 454 Life Sciences.

Patrick J. Zenner, a CuraGen board member and former President and Chief Executive Officer of Hoffmann-La Roche, Inc. was appointed by the Board as Chairman and Chief Executive Officer of CuraGen on an interim basis, until completion of the ongoing search for a new Chief Executive Officer.

Christopher K. McLeod, CuraGen Executive Vice President, has been named President and Chief Executive Officer of 454 Life Sciences, on a full-time basis.

"With the signing of a major partnership between 454 Life Sciences and Hoffmann-La Roche, CuraGen`s Board of Directors believes that it is the appropriate time to make executive changes that best leverage the value of CuraGen`s promising therapeutic pipeline, as well as our majority ownership in 454," said Patrick J. Zenner. "With a very capable executive team in place, I am excited to help lead CuraGen forward, on an interim basis, as we aggressively continue the search for a permanent CEO."

"With a tremendous new partnership between 454 and Roche for worldwide promotion and distribution of our breakthrough technology, I want to focus on assisting 454 Life Sciences to become a self-sustaining and profitable company. I will stay active through participation on CuraGen`s Board of Directors and as a consultant to CuraGen, but my scientific talents and strategic vision are best suited for 454," stated Jonathan M. Rothberg, Ph.D.

The search for a new Chief Executive Officer was initiated in April following Dr. Rothberg`s announced decision to step down as Chief Executive Officer of CuraGen.

[bonDiacomova]

quelle : MarketWatch By Steve Goldstein


CuraGen unit inks license deal from Roche

CuraGen Corp. said its 454 Life Sciences division has agreed to a five-year deal with Roche Holding where it will receive $62 million in fees plus royalties for the promotion, sale and distribution of nanotechnology-based Genome Sequencing Systems.

[bonDiacomova]

akt kurs 4,21 $


CuraGen and TopoTarget Announce Cooperative Research and Development
Agreement with the National Cancer Institute for PXD101

http://biz.yahoo.com/prnews/050512/neth012.html?.v=10

[bonDiacomova]

zu # 84

454 Life Sciences and Roche
Enter Exclusive World-Wide Agreement
for Ultra High-Throughput Genome Sequencing System

BRANFORD, Conn. and BASEL, Switzerland, May 12 /PRNewswire-FirstCall/

454 Life Sciences, a majority-owned subsidiary of CuraGen Corporation (Nasdaq: CRGN), and Roche today announced they have entered into an exclusive 5-year world-wide agreement for the promotion, sale, and distribution of 454 Life Sciences` nanotechnology-based Genome Sequencing Systems, including proprietary kits and reagents. The technology used in the 454 Genome Sequencing System enables researchers to sequence up to 100 times faster than current commercial platforms. 454`s proprietary technology represents the first radically new approach for sequencing to be commercialized since Gilbert and Sanger won the Noble prize for DNA sequencing in 1980.

Under the terms of the 5-year, exclusive world-wide distribution agreement, 454 will receive a margin on products manufactured for Roche Diagnostics, and royalties on net sales of licensed products. 454 will receive up to $62 million dollars in license fees, milestones related to instrument releases, minimum royalties and research funding. Roche Diagnostics receives the rights to negotiate distribution of 454 Life Sciences` products in the regulated diagnostic market and renewal of the distribution agreement contingent upon meeting minimum performance criteria.

"Customer feedback and our own research show that one of the main limitations of today`s approaches to sequencing lies in throughput. This new technology will significantly increase the speed and decrease the cost of sequencing, and thereby has the potential to open up many new applications for sequencing to researchers all over the world," stated Heino von Prondzynski, CEO of Division Roche Diagnostics and Member of the Roche Executive Committee. "Roche Diagnostics can enter now a new and very attractive market that complements our strong position in research applications."

Under the agreement, Roche Applied Science, a business area of Roche Diagnostics, will sell 454 Life Sciences` products through their extensive sales and marketing teams, distribute 454`s products through Roche Diagnostics` established supply chain, and provide technical support to purchasers of the 454 Genome Sequencing System and the associated reagents. 454 Life Sciences will continue to manufacture instrument systems and reagent kits, with the option to transfer the responsibility for reagent manufacturing to Roche Diagnostics given sufficient sales volume. The agreement allows for Roche Diagnostics to sell 454`s products to all markets, with the exception of regulated diagnostics, where Roche Diagnostics obtained an exclusive right to negotiate the extension of the exclusive distribution agreement into the regulated diagnostics market during the initial 5-year term.

"Roche continues to be a pioneer in identifying revolutionary technologies and I am pleased that they will be an integral part of accelerating the full potential of 454 Life Sciences` sequencing technology for researchers world- wide," stated Christopher K. McLeod, President and Chief Executive Officer of 454 Life Sciences. "We are delighted to have the chance to use the strength of their organization to expand our commercialization efforts and bring 454`s novel nanotechnology to a broader market, and assist us in achieving our goal of financial self-sufficiency. We believe that 454 Life Sciences` technology will enhance the generation of genomic data and sequencing applications, enabling the discovery, development, and clinical testing of new vaccines and drugs, and allowing personalized medicine to become a reality."

454 Life Sciences began commercialization of instrument systems and proprietary reagents during the first quarter of 2005, with the initial instrument system sale to the Broad Institute of MIT and Harvard, led by Dr. Eric Lander. The agreement with Roche Diagnostics will broaden the reach of 454 Life Sciences products, and enable 454 Life Sciences to focus on research and development of next generation technology and applications for high throughput sequencing.

454`s system enables one individual to prepare and sequence an entire genome after performing a single sample preparation, irrespective of the size of the genome being studied. The hallmark of 454`s technology is the nanotechnology-based approach to sequencing which allows a single instrument to produce over 20 million nucleotide bases per four hour run, totaling more that 100 times the capacity of instruments using the current macro-scale technology. 454`s technology is based on integrating proprietary picoliter- technologies (a picoliter is a billionth of a liter), patented light emitting sequencing chemistries, and state of the art informatics. The patented Genome Sequencing System utilizes this technology and is a scalable, ultra-fast and cost-effective system with applications for whole genome sequencing and deep sequencing of genes of interest.

About 454 Life Sciences

454 Life Sciences is commercializing novel instrumentation and services for rapidly and comprehensively conducting high-throughput nucleotide sequencing, with specific application to sequencing of whole genomes and ultra deep sequencing of target genes. The Company`s instrument systems, based on proprietary nanoscale technologies, patented light emitting sequencing chemistry, and state of the art image processing and informatics, have 100 times the throughput of existing sequencing machines. 454 is marketing its services and instruments to pharmaceutical, biotechnology, biodefense, and agriculture companies as well as to universities and government agencies. 454 Life Sciences is a majority owned subsidiary of CuraGen Corporation (Nasdaq: CRGN - News). Additional information is available at http://www.454.com.

About Roche and the Roche Diagnostics

Headquartered in Basel, Switzerland, Roche is one of the world`s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people`s health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2004 sales by the Pharmaceuticals Division totaled 21.7 billion Swiss francs, while the Diagnostics Division posted sales of 7.8 billion Swiss francs. Roche employs roughly 65,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai.

Roche`s Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide.

[bonDiacomova]

454 Life Sciences Presents Detection Breakthrough at XIV International HIV Drug Resistance Workshop

- 454`s ultra-deep sequencing able to detect low levels of drug resistant HIV -


BRANFORD, Conn., June 9 /PRNewswire-FirstCall/

454 Life Sciences, a majority-owned subsidiary of CuraGen Corporation (Nasdaq: CRGN), reported today that scientists from the Company presented a poster detailing a potentially new application for the Company`s technology -- ultra-deep sequencing of the HIV virus. The poster, in addition to an oral presentation on Friday, June 10, at the XIV International HIV Drug Resistance Workshop in Quebec City, Quebec, Canada, discusses the ability of 454`s sequencing platform to rapidly, reproducibly and accurately detect minor HIV variants that contain drug resistance mutations present in HIV-infected patients.

ADVERTISEMENT

Identifying and understanding HIV drug resistance is necessary to ensure the appropriate use of antiretroviral drugs and to minimize the spread of resistance. In the United States, up to 50% of HIV-infected patients receiving drug therapy are infected with drug resistant virus. Improved detection of minor variants in the HIV virus could ultimately assist researchers in the development of new HIV therapeutics and help physicians tailor drug regimens for HIV-infected patients.

454`s technology can identify and accurately quantify sequence variants present in very low levels, comfortably less than 1% of any mutation. In comparison, traditional technologies are unable to detect minor HIV variants that confer drug resistance unless greater than 10-20% of a circulating virus contains a known genetic mutation.

"The ability to detect minor populations of drug resistant HIV strains circulating in patients` blood could greatly facilitate researchers` understanding of HIV drug resistance," commented Michael Kozal, M.D., Associate Professor of Medicine, Yale University School of Medicine. "454`s technology allows us to see emerging variations at a level not currently possible with traditional sequencing technology and could foster a better understanding of response to antiretroviral therapy and lead to improved treatment regimens for patients."

The poster and anticipated oral presentation, entitled "Ultra-Deep Sequencing of HIV from Drug Resistant Patients," detail the use of 454 Life Sciences` nano-based technology to produce 1000-fold more sequencing reads per run than traditional sequencing methods achieving massive over-sampling of the HIV virus and enabling the identification of low-level mutations in different sequence variants. The proof-of-concept study demonstrates 454`s ability to perform ultra-deep sequencing potentially allowing for a more sensitive and accurate method to determine HIV genetic variations.

[bonDiacomova]

akt kurs 5.14 $

CuraGen Presents New Preclinical Data on Velafermin
at the 17th Annual International Symposium on Supportive Care in Cancer

Thursday June 30, 4:30 pm ET

-- Activity for the prevention of radiation-induced enteritis demonstrated in animal models --

NEW HAVEN, Conn., June 30 /PRNewswire-FirstCall/ CuraGen Corporation (Nasdaq: CRGN) announced today that scientists from the Company reported new preclinical data on velafermin (CG53135), CuraGen`s Phase II clinical product being developed for the prevention of oral mucositis (OM), suggesting that velafermin may protect the gastrointestinal tract and decrease associated toxicity, including enteritis and diarrhea, following exposure to radiation.

In a poster presentation entitled, "Parenteral administration of velafermin (rhFGF-20) reduces radiation-induced gastrointestinal syndrome in vivo," it was reported that the incidence of enteritis and diarrhea for animals treated with velafermin was reduced up to 50%. The poster, presented this week at the 17th Annual International Symposium on Supportive Care in Cancer held by the Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO), June 30 - July 2 in Geneva, Switzerland, was also selected for the Best of MASCC Poster Award: Questions in Mucositis Research, and will be featured in an oral presentation on Saturday, July 2 from 11:40 - 11:50am.

"Both chemotherapy and radiation could affect the entire length of a cancer patient`s gastrointestinal tract. These results suggest that velafermin may play a broader role in cancer supportive care by addressing not only oral mucositis, but potentially for the management of enteritis and diarrhea," stated Timothy M. Shannon, M.D., Executive Vice President and Chief Medical Officer at CuraGen. "As we continue to advance velafermin through Phase II for the prevention of oral mucositis, these data will support our future intentions of evaluating velafermin for additional indications."

Reprints of the poster presentation are available by emailing [e-mail]. Additional information about CuraGen`s ongoing clinical trials and pipeline of therapeutics are available on the Company`s website, http://www.curagen.com.

Background on Velafermin and Oral Mucositis (OM)

Velafermin is a novel fibroblast growth factor discovered by CuraGen that appears to promote both epithelial and mesenchymal cell proliferation. Velafermin is currently being investigated in clinical trials for the prevention and treatment of OM, a side effect experienced by cancer patients undergoing chemotherapy or radiation therapy. OM is characterized by inflammation and ulceration of the tissue lining the mouth and throat, leading to bleeding, pain, and difficulty eating and drinking, but may also affect the entire lining of the gastrointestinal tract. OM is sometimes a cause for clinicians to interrupt patients` cancer treatment regimens, potentially limiting the success of therapeutic plans. An effective therapy for OM has the potential to treat debilitating symptoms, to allow cancer patients to better tolerate the appropriate doses of cancer treatment, and to decrease hospitalization time.

Velafermin is currently in a Phase II randomized, placebo-controlled clinical trial investigating its role in the prevention of OM for patients receiving high-dose chemotherapy followed by a bone marrow transplantation. This trial is expected to be complete during the first half of 2006. Velafermin is also being evaluated in a Phase I study for the treatment of OM by being administered to patients after the onset of early signs of OM in order to assess its safety and potential effect on the duration of and progression to severe OM. CuraGen expects to complete this trial by the end of 2005.

[bonDiacomova]

[bonDiacomova]

akt kurs 5.24 $

CuraGen Announces Pricing of Common Stock Offering

NEW HAVEN, Conn., Aug. 10 /PRNewswire-FirstCall/ --

CuraGen Corporation (Nasdaq: CRGN) today announced the pricing of its public offering of

4,000,000 shares of its common stock at a public offering price of $5.50 per share.

The proceeds of the public offering will be approximately $21.0 million, after underwriting discounts and before expenses. The Company intends to use the net proceeds from this offering to repurchase, from time to time, its 6% convertible subordinated debentures due February 2007 and for general corporate purposes. All of the shares are being offered by CuraGen.


Bear, Stearns & Co. Inc. is acting as the underwriter in the offering.

[lottojan10]

gibt es hier noch jemanden der investiert ist

[lottojan10]

hey ihr schnarchsäcke

keiner mehr ausser mir der an crgn glaubt

schade

cu lotto

[Preacher]

Hi, habe auch noch ein Päckchen CGN aus besseren Tagen; liege bei 70 % Verlust, war jedoch standhaft und habe Einstand nie verbilligt.
Besitze auch noch Millennium, HGS, Orchid Bio (heißen jetzt irgendwie anders, kann mich noch nicht an den neuen Namen gewöhnen), PDLI, Myriad, Vertex und Gilead. Die beiden letzten machen viel Freude und werfen dicke Gewinne ab. Bei PDLI und Myriad habe ich leichte Gewinne. Kummer machen die anderen vier Positionen. Ich wollte HGS, Orchid und CGN "opfern" (=verkaufen und abschreiben) und das frische Geld evtl. in Millennium stecken. Warum sollte man eurer Meinung nach CGN behalten??? Gibt es irgendein neues Argument ausser "Hoffnung"?
Gruß Preacher

[bonDiacomova]

bon domingo

" Gibt es irgendein neues Argument "

charttechnik



die 3 hat gehalten

¿ gap schluss ?

[lottojan10]

hi dicomova,

was `n das fürn kritelkratzel

sieht aus wie aus ner börsenzeitung

ne aber mal spaß bei seite hab von charttechnik keine ahnung, was sagt der chart?

hatte irgendwie gehofft, daß die jetzt mal so gut laufen könnten wie meine medx, news habe ich auch schon lange keine mehr gehört.

ach so bevor ich es vergesse, toll daß noch ein par außer mir hier drinn sind und auch mal wieder was posten


vielen dank dafür und lasst uns die bude nicht ganz vergessen

viele liebe grüße

lotto

[Preacher]

Hi,
bin auch kein Techniker, aber das mit dem "gap" könnte bedeuten, dass CGN zur Schließung des Gaps steigen müßte. Ziel bei 4-5 USD. Stimmts?
Wäre auf jeden Fall ein ganz netter Anstieg vom heutigen Niveau.
Gruß
Preacher

[lottojan10]

ja wäre sehr schön, dann bräuchte ich nur noch 400 % um wieder bei meinem einstiegskurs zu sein lol


grüße lotto

[lottojan10]

@ alle

sach mal ist hier niemand der regelmäßig schaut was crgn so macht???????

schnarch

lotto freut sich auf rege anteilnahme


danke

[bonDiacomova]

bon domingo

niemand - wenige



noch " ziert " sie sich das gap zu schliessen

-----
454 Life Sciences Installs Twenty GS20 Systems
in the First Year of Sales - http://biz.yahoo.com/prnews/060111/nyw152.html?.v=37

454 Life Sciences financial results for 2005
and guidance for 2006 will be reported on

---> February 2, 2006

in conjunction with CuraGen Corporation`s fourth quarter and 2005 year-end results press release.

[lottojan10]

@ bondiacomova

schön, daß du hier immer mal was reinstellst, danke dafür.

wenn am 02.02.06 berichte über finanzen kommen, kann das ja eigentlich nur heißen, daß prognosen ei ngehalten, übertroffen oder nicht erreicht wurde.

hat doch aber wenig mit der pipline zu tun oder?

frage mich eigentlich warum es die immer noch gibt, man hört seit jahren nix und der kurs, naja siehst ja selber.

nun meine frage:

hab zwar nur 100 st./23€ , aber da die immer noch da sind, und andere längst die flügel fallen gelassen haben,könnte ich doch noch mal 200 einsammeln oder, dann bin ich bei 9,60 € und die werden sie vielleicht doch mal wieder haben oder ?

vielen dank für antwort

lotto

[bonDiacomova]

gerne jan

nun wenn crgn zu den zahlen
auch einen ausblick zu 454 Life Sciences geben will
im zusammenhang mit den zahlen 2005 und 4. quartal 2005
- normal das ganze wuerde ich sagen...
denke dass sie sich noch etwas erwarten in der zukunft...

wenn es ---> gut laeuft
sollten 10 oder auch 20 eus drinne sein

falls Du in 2005 zu versteuernde gewinne erzielt hast
verkaufe Deine alte posi

falls Du neu investieren willst
denke nicht an die alten einstiegskurse

bewerte das unternehmen immer wieder aktuell
es ist egal was man mal dafuer bezahlt hat

saludos bd

[lottojan10]

na also jetzt kanns also los gehen, denke bis 5 € gehts hoch oder was sagen die charttechniker ?

lotto

[bonDiacomova]

[posting]19.968.776 von lottojan10 am 31.01.06 09:00:34[/posting]das gap ist zu

nun wird sich zeigen wohin die reise geht



BULLISH
Probability - Intermediate trend bullish, Downtrend turned sideways, possible bottom.
Confirmation - Strong bullish 3 day chart pattern.


BEARISH
Probability - Overbought, odds favor short trades.
Probability - Short term typical rally, rally may start to slow.
Confirmation - Extreme 3 day accumulation, but when the stock is overbought this is considered bearish.
Confirmation - Extreme bearish 1 day moneyflow
Probability - Strong Up trend (1 month), may start to turn sideways.
Confirmation - at resistance

[bonDiacomova]

[posting]19.976.508 von bonDiacomova am 31.01.06 16:12:00[/posting]eigentlich - die gaps

[lottojan10]

heut wird sichs zeigen, bin mal gespannt obs geht oder nicht

lotto

[lottojan10]

ok sieht nicht gut aus, ausbruch bis auf 5 lässt auf sich warten.

macht nix wir warten schon lang genug oder ?

lotto

[bonDiacomova]

bon dia

BRANFORD, Conn., Feb. 2 /PRNewswire-FirstCall/

CuraGen Corporation (Nasdaq: CRGN ) today reported its consolidated financial results for the fourth quarter and fiscal year ended December 31, 2005.

ADVERTISEMENT

For the year ended December 31, 2005, CuraGen`s consolidated net loss was $73.2 million, or $1.41 per share, compared to a net loss of $90.4 million, or $1.81 per share, for fiscal year 2004. The net loss for the fourth quarter of 2005 was $15.6 million, or $0.29 per share, compared to a net loss of $22.7 million, or $0.45 per share, in the fourth quarter of 2004.

As of December 31, 2005, CuraGen had available cash and investments of $226.5 million, and had outstanding 6% convertible debt of $66.2 million, due February 2007, and 4% convertible debt of $110 million, due February 2011. Net operating cash burn for 2005 was approximately $61 million, excluding net cash used of approximately $41 million for the repurchases of outstanding 2007 convertible debt.

Total consolidated revenues for the year ended December 31, 2005 were $23.5 million, compared to $6.3 million in 2004. Total consolidated revenues for the fourth quarter 2005 were $10.6 million, compared to $1.1 million in the fourth quarter of 2004. In the fourth quarter of 2005, 454 Life Sciences, a majority-owned subsidiary of CuraGen, recognized $7.3 million in revenue from sales of instrument systems and proprietary reagents, fee for service sales and royalties, as well as $0.9 million in grant revenue.

"CuraGen and 454 Life Sciences both achieved significant milestones in 2005 and we look to accelerate our momentum throughout 2006. At CuraGen, we successfully focused our resources on our most advanced oncology assets, including velafermin, PXD101 and CR011. We carefully managed our cash burn, reduced our outstanding 2007 convertible debt, and modified our agreement with Bayer for the development of BAY 76-7171 to allow for the continued development of this asset without diverting resources from our oncology pipeline," stated Patrick J. Zenner, Interim Chief Executive Officer and Chairman of CuraGen. "In 2005, 454 Life Sciences emerged as a leader in whole genome sequencing technology with the launch of their Genome Sequencer 20 System, the signing of an exclusive distribution agreement with Roche, and the achievement of $19 million in milestone payments related to the Roche distribution agreement."

"CuraGen has made significant progress advancing its pipeline. Our Phase II trial results with velafermin suggest potentially meaningful single-dose activity of velafermin for the prevention of oral mucositis at a safe and well-tolerated dose. We initiated several proof-of-concept trials with our HDAC inhibitor, PXD101, evaluating its role in the treatment of multiple myeloma, ovarian and colorectal cancers, and more recently, in a myeloma study of PXD101 in combination with Velcade® and as a single-agent therapy for T- cell lymphoma. We also made the necessary investments to advance CR011, an antibody-drug conjugate for metastatic melanoma, toward clinical trials that we expect to initiate during the first half of 2006," commented Timothy M. Shannon, M.D., Executive Vice President of Research and Development and Chief Medical Officer. "Later this month, our investigators will present the Phase II prevention and Phase I treatment results on velafermin at the BMT Tandem Meetings. After the presentation of these data, we look forward to reviewing the Phase II results and providing an update on the clinical development plan for velafermin during a conference call on February 21, 2006."

"In 2005, 454 Life Sciences emerged as a leader in next-generation sequencing technology, highlighted by the launch of the Genome Sequencer 20 System, first by us to select clients, and then through our exclusive distribution partner, Roche Applied Science. In the fourth quarter, 454 Life Sciences and Roche more than doubled the number of installed instrument systems, as compared to the first nine months of 2005, resulting in a year-end total of twenty Genome Sequencer 20 Systems being used by researchers across the United States, Europe and Asia, with some clients using multiple instrument systems at their institutions," stated Christopher K. McLeod, President and Chief Executive Officer of 454 Life Sciences. "In 2006, we aim to grow our contract sequencing services revenues at our Measurement Services Center, while simultaneously working with Roche to increase the sales of the Genome Sequencer 20 System and reagents to clients around the globe."

2006 Guidance: Financial Outlook

CuraGen`s consolidated net loss for 2006 is projected at $70 to $75 million. During 2006, CuraGen plans to continue making research and development investments in its clinical and preclinical oncology pipeline and, as a result, management foresees that consolidated 2006 research and development expenses will range from $65 to $70 million. CuraGen expects that general and administrative expenses will be approximately $23 million, an increase as compared to 2005 related primarily to the support of 454 Life Sciences` continued growth.

Consolidated revenues for 2006 are expected to range from $35 to $38 million. 454 Life Sciences` revenues, included in consolidated CuraGen revenues, are expected to grow from $18.7 million in 2005, to $30 to $35 million in 2006. During 2006, 454 Life Sciences expects to have continued revenue growth from sequencing services provided at their Measurement Services Center, as well as from the sale of instruments and reagents through Roche Applied Science under their exclusive 5-year license, supply and distribution agreement.

Interest income for 2006 is anticipated to decrease to approximately $5.5 million due to decreasing cash balances, and interest expense is expected to decrease to approximately $9.5 million. Capital expenditures are expected to be approximately $3.5 to $4 million in 2006. Depreciation and amortization expenses are anticipated to be approximately $10 million in 2006, compared to $8.8 million in 2005.

Consolidated cash burn for 2006 is anticipated to be approximately $70 to $75 million, including approximately $7 to $15 million at 454 Life Sciences in support of their continued investment in next-generation sequencing technologies.

454 Life Sciences: Upcoming Product Releases :
http://biz.yahoo.com/prnews/060202/neth018.html?.v=38

[bonDiacomova]

[posting]20.032.063 von lottojan10 am 03.02.06 17:36:15[/posting]moin loddo

halte eine seitwaerts abwaerts bewegung am wahrscheinlichsten

die idikatoren bei www.stockconsultat.com sehen nicht gut aus :

Overall Summary:
30%, Bullish
70%, Bearish

Trade Quality:
Upside: 45%, Poor
Downside: 100%, Excellent

BULLISH
Probability - Mild bullish 3 day chart pattern.


BEARISH
Probability - Intermediate trend possibly bearish, Sideways trend near upper resistance.
Probability - Overbought, odds favor short trades.
Probability - Short term typical rally, rally may start to slow.
Confirmation - Extreme 3 day accumulation, but when the stock is overbought this is considered bearish.
Confirmation - Extreme Neutral 1 day moneyflow, on an strong-extreme rally is considered bearish.
Probability - Strong Up trend (1 month), may start to turn sideways.
Confirmation - at resistance

der chart ... halte 3.50 $ vll sogar naehe 3 fuer moeglich...

[lottojan10]

@ bondia

denk ich leider auch, also in lauerstellung verharren und beobachten

ps kommst du aus hamburg ???

ich bin aus hh

grüße lotto

[bonDiacomova]

moin loddo

schleswig holstein - westkueste
wo der wind aus allen 4 eggen blaest

lebe seit 90 auf mallorca
nicht nur wegen dem besseren wedder

gruesse in den hohen norden hummelhummel

[lottojan10]

ein freundliches moin zurück bon dia !!!

war gerade letztes wochenende auf malle

haben in einem alten schafstall spanferkel gegessen, kennst du bestimmt, geht so serpentinen hoch, daß man denkt oben kommt die louis tränker gedächtniss kirche

war aber sehr geil da oben.

schlechtes wetter habt ihr glaube ich gerade oder ??

naja, geht auch vorbei.

viele grüße

lotto

[lottojan10]

jetzt gehts also doch los, amis legen aber mächtig vor

manchmal sollte man auf den bauch höhren oder ?

[bonDiacomova]

mensch das ja ein - quatsch mind. - 2 dingen

- Du warst gerade hier
- Piper Jaffray Upgrade
from Market Perform to Outperform

jo - wedder gerade nich so dolle

saludos y suerte bd

[bonDiacomova]

p.s. weisst Du noch den namen des stalles
gibt einiges an staellen und serpentinen

[lottojan10]

buenas dias bon dia,

der Schafstall war in alaro bei inca soll angeblich jeder mallorcaner kennen,

war richtig geil, wo wohnst du denn, wir haben in llucmajor
in einer alten cinka gewohnt war ein nettes wochenende.

war total entäuscht vom ballermann, dachte da gehts richtig ab, waren aber auch nur am tag da um mal zu gucken, war das erste mal auf malle, hat mir aber voll gut gefallen, so tourimäßig ist das ja gar nicht, hatte aber auch nen guten guide, meine freundin, die war schon sehr oft da, ihre eltern leben auch auf malle.

so haben wir ein upgrate bekommen, daher die 10 % ?

naja habe mal wieder nicht nachgekauft, aber bei crgn gehts ja auch bestimmt wieder unter 3 € und den nächsten hype nehme ich dann mit.

in deutschland werden die ja fast nicht gehandelt, heute glaube ich 1000 st in fra. oder ?

meinst die kriegt man dann überhaupt ??


grüße lotto

[bonDiacomova]

bon dia loddo

jo¡O - der stall hinter alaro ist bekannt

wir wohnen von inca 7 km richtung st. margalida
in einen kleinen dorf - 2000 einwohner
auch von sineu [geographischer mittelpunkt der insel] 7 km

ballermann da war ich in 15 jahren noch nicht des nachts

es ist eine tolle insel - schoen daste "fuehrung" hattest
so kann man mallorca ´richtig` kennen lernen

sach das naechste mal man bescheid bevor Du kommst

---


---> so haben wir ein upgrate bekommen, daher die 10 % ?
- si señor - auf Piper Jaffray hoeren ne ganze menge "anleger"

---> in deutschland werden die ja fast nicht gehandelt,
heute glaube ich 1000 st in fra. oder ?

19:43:43 3,80 65
17:03:23 3,78 1.000
12:11:05 3,50 0
09:00:16 3,29 0

Times & Sales : http://www.is-asp.pbc.maxblue.de/is-asp/mare0839_cont.html?s…

wenn ich crgn kaufe/verkaufe dann in usa

¿ bei welchem broker bist Du ?

saludos y suerte bd

[bonDiacomova]

CuraGen Stock Jumps on Upgrade Over Drug

CuraGen Stock Jumps on Upgrade Over Multiple-Myeloma Drug


NEW YORK (AP) -- The stock of CuraGen Corp. rose sharply Monday after Piper Jaffray raised its investment rating on the biotechnology company`s shares, citing the potential of two new products.

In midday trading, CuraGen shares rose 52 cents, or 13 percent, to $4.53 on the Nasdaq Stock Market.

ADVERTISEMENT

Piper Jaffray, which upgraded CuraGen to "outperform" from "market perform," cited the potential of PXD101, a therapy to help patients with multiple myeloma, a form of cancer marked by the wild proliferation of plasma cells found in the bone marrow.

PXD101 is in Phase II clinical trials. The mid-stage test results are expected to be released in mid-2006, according to CuraGen, based in Branford, Conn.

Piper Jaffray analyst Edward Tenthoff said he`s interested in a move to combine PXD101 with Cambridge, Mass.-based Millennium Pharmaceuticals Inc.`s drug Velcade, which is being co-developed by New Brunswick, N.J.-based Johnson & Johnson. Piper Jaffray said it believes using PXD101 with Velcade will result in higher rates of responses to the drug.

The investment company also cited CuraGen`s 454 LifeSciences` Genome Sequencer, launched in October, for the ratings upgrade.

454 LifeSciences, 66 percent owned by CuraGen, recently launched the Genome Sequencer 20 system with Indianapolis-based Roche Diagnostics Corp. and received a $7.5 million milestone payment.

Piper Jaffray increased its 12-month price target on CuraGen to $6.50 a share from $6.10, and raised its 2006 target revenue estimate to $36.7 million.

The company expects 2006 revenue between $35 million to $38 million. In 2005, CuraGen posted revenue of $23.5 million.

[bonDiacomova]

kaum sind die beiden gaps geschlossen
haben wir ein neues...

ein "up and away" gap aufgrund einer empfehlung... mir fehlt der glaube...

[lottojan10]

ola , bon dia

hat mir auch sehr gut gefallen deine neue heimat,
auf ballermann bin ich eh nicht scharf.

zum broker:

du wirst dich jetzt bestimmt tod lachen, ich bin bei dem onlinebroker der stadtsparkasse, vorher direkt über die stadtsparkasse.

in der hinrichtung bin ich warscheinlich ein wenig hinter her oder ?

aber welche vorteile bieten ander broker ?

aufklärung wäre sehr schön.

also bon dia, lotto wünscht dir einen schönen tag und tolles wetter.

bei uns schneits übrigens

ps
lebe auch seit 1990 nicht mehr in hh, bin jetzt bei münchen angesiedelt.

lotto

[lottojan10]

hey bon dia

gib zu du sitzt im schafstall bei lamm und vino tinto,
desshalb hör ich nix von dir.
können die nicht ne wab cam installieren, dann kann ich dir zuschauen und mich über den schnee hier ärgern.

viele grüße lotto

[bonDiacomova]

bon dia loddo

zu Deinem p.s. - und bayernfan geworden ¿?¿

das wedder ist wesentlich besser geworden
die mandelbaeume bluehen
mittags steigen die themperaturen auf 17 grados

ich weiss ueber den broker der sparkassen nichts

daher kann ich Dir leider nicht sagen
was andere broker me¡er zu bieten haben...

auf jedenfall finde ich wichtig

- sich den boersenplatz zum handeln selber auszusuchen
also im falle von crgn direkt in den staaten
- bietet Dein broker direkttrade ¿?¿
- gebuehren - z.B. keine teilausfuehrungskosten

te deseo un bon dia bd

[lottojan10]

ola bon dia

bin larm arsch, desshalb so späte antwort.

1 musste noch nie über usa handeln#

2 teilausführungen kosten mich nicht mehr

3 bin immer schon bayern fan gewesen, auch in hh

4 st pauli - bayern mein tipp 20 : 01

5 bei punkt 4 ist leider wunsch, vater des gedankens

6 wenn ich nächstes mal auf malle bin würd ich dich sehr gerne kennen lernen

7 ich glaube crgn ist kein zukunftsträchtiges investment

hoffe aber immer noch meine verluste ausgleichen zu können


hier ist voll der schneesturm, ganz bayern bangt um seine dächer.

und trappa toni sucht nen neuen job

ich wünsche dir/euch ein schönes wochenende


schreib dir nächste woche mal ne bm, dann können wir ja mal gucken ob du mich auch kennen lernen möchtest



liebe grüße aus nem großen schneehaufen

lotto

[bonDiacomova]

bon domingo loddo

zu 6 : sehr gerne

zu ---> schreib dir nächste woche mal ne bm : oki

saludos y suerte bd

[lottojan10]

moin,

so jetzt haben wir die 5 €, ging aber ganz schön schnell,

wie weit gehts bon dia ?

was meinst du ?

grüße lotto

[lottojan10]

und geht immer schneller?

was ist da los usa hat doch heut frei, gibts neuigkeiten???

lotto

[lottojan10]

ola bon dia,

bist du seit einer woche in alero im schafstall ?

deine einschätzung zur letzten woche wäre eine wohltat

dein lotto

[bonDiacomova]

bon dia loddo

echt ne menge am hut hier z.Z.
die ereignisse ueberschlagen sich

crgn :

stochi und macd " vor der entscheidung "
bollinger baender weit offen...
ich persoenlich rechne mit schliessung des gaps
denke nicht dass`is ein braek away gap ist - schaun mer mal

bon fin de semana bd



BULLISH
Probability - Mild bullish 3 day chart pattern.

BEARISH
Probability - Intermediate trend bearish, Unsustainable uptrend, may turn sideways.
Probability - Extreme Overbought, odds definitely favor short trades.
Probability - Short term strong rally, rally may start to slow.
Probability - Excessive Up trend (1 month), not sustainable, occurs only 10% of the time, expect trend to turn sideways or lower.
Confirmation - at resistance

[lottojan10]

@ bon dia


hoffe auf malle ist alles im grünen bereich.

unser crgn hat sich wohl doch für einen urlaub im süden entschieden, hoffe nur, daß das kein jahres ticket ist



viele güße lotto

[bonDiacomova]

das gap ist geschlossen - schaun mer mal ob die 4 haelt
falls nicht test der 3,60 - vll sogar der 3

begr. : der alte boersenspruch sell in may and...

[lottojan10]

denke bei 2,50 könnte man wieder erste positionen aufbauen, was meinst du bon dia ?

diesmal möchte ich nicht hinterher humpeln


viele grüße
lotto

[lottojan10]

na also waren die 2,45 € gestern doch gar nicht so schlecht, mal sehen was weiter geht.

lotto

[lottojan10]

schöner tag für crgn, wieder über 5 % im plus,usa :rt 3,47 $,

mal sehen ob sich die sache so entwickelt, wie ich das gern hätte, ende juli kurse um die 4,50 €, hat in den letzten 1 1/2 jahren ja schon 3 mal geklappt.

schönes wochenende.

und viele grüße an bon dia, lass mal wieder was von dir hören.

lotto

[lottojan10]

scheint so als ob niemand mehr an bord ist

rt usa 3,70, bis lang läuft die sache ja

ct, bon dia, wenn es etwas bringt, würde mich interessieren.

grüße nach malle

lotto

[bonDiacomova]

bon dia loddo

bin voll in wm vorbereitungen
fliege zur WM nach D

siehe #129
es ging auf die 3 [3,02]
vll noch einmal ¿ ein W ?

saludos y suerte bd


BULLISH
Probability - Intermediate trend possibly bullish, Sideways trend near lower support.
Confirmation - Strong bullish 3 day chart pattern with Mild 3 day accumulation.
Probability - Strong Down trend (1 month), may start to turn sideways.

BEARISH
Probability - Short term typical rally, rally may start to slow.
Confirmation - at resistance

[lottojan10]

moin bon dia,

danke für deine antwort, die mich übelegen lässt bei crgn doch nach den gewinnen der letzten woche wieder raus zu gehen.

ansonsten, geil du insulaner , fährst in die heimat um fußball zu gucken, neid, neid, neid.

wo bist du denn ???

wenn in münchen, dann stelle ich ein weißbier kalt, falls du lust und zeit hast.

viele grüße lotto

[lottojan10]

da ich scheinbar monologe halte hier im thread, ist ja auch egal, hier ein weiterer:

bin zu 2,80 wieder raus und wie man heut sieht gibts morgen nachmittag wohl die 2,45 wieder.

kaufe diesesmal aber erst bei 2,35.

viele grüße an alle,

meine damit dich bon dia, und natürlich mich
lotto

[bonDiacomova]

moin loddo

.... im hohen norden

laeuft alles sehr gut - mit dem fussie und soo

crgn hohe wahrscheinlichkeit auf die 3

[hri]

Press Release Source: 454 Life Sciences


Dana Farber and 454 Life Sciences Announce Breakthrough in DNA Sequencing for Cancer Research
Sunday June 25, 1:00 pm ET
- Sequencing Method Detects Cancer Mutations at the Molecular Level -


BRANFORD, Conn., June 25 /PRNewswire/ -- 454 Life Sciences Corporation, a majority-owned subsidiary of CuraGen Corporation (Nasdaq: CRGN - News), in collaboration with scientists at Dana Farber Cancer Center and Broad Institute, today reported a new method for the detection of cancer gene mutations present at extremely low levels. The research, published online (ahead of print) in the journal Nature Medicine, describes how the 454 Sequencing(TM) method identifies rare cancer-associated genetic variations at the molecular level, potentially enabling the personalization of targeted therapies. The title of the article is: 'Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing.'
ADVERTISEMENT





454 Sequencing(TM) technology was used to analyze mutations in five exons of the Epidermal Growth Factor Receptor (EGFR) gene in tumor samples from 22 patients with lung cancer. The EGFR gene is the target for several new anti- cancer drugs called EGFR inhibitors. This research proposes that 454 Sequencing(TM) may help to validate the ability of EGFR mutations to predict patient responsiveness to treatment with an EGFR inhibitor.

It has been realized that genetic mutations are responsible for sensitizing some tumor cells to chemotherapy, while other mutations render tumor cells completely resistant to drug treatments. Historically, research progress has been slowed by the complex mix of cells in a tumor sample, compounded by cost-prohibitive, conventional low-resolution sequencing methods that lack sufficient accuracy to characterize the DNA in cancerous cells. 454 Sequencing(TM) is the first advanced sequencing technology that can generate hundreds of thousands of DNA sequences in one run, rapidly and comprehensively conducting high-throughput nucleotide sequencing, with specific application to sequencing of whole genomes and ultra-deep sequencing of target genes. By enabling a method of sequencing that is more comprehensive and less expensive than conventional sequencing methods, 454 Sequencing(TM) may be used in medical research settings to detect cancer-associated genetic mutations.

"Analysis of DNA from tumors is complicated by varying amounts of tumor cells in patient samples. Furthermore, the heterogeneous nature of many tumors makes it difficult to accurately sequence the tumor DNA, which is required in order to personalize treatment," explained senior author of the study, Matthew Meyerson, M.D. Ph.D., of Dana Farber Cancer Center and Broad Institute. "454 Sequencing may facilitate accurate molecular diagnosis of heterogeneous cancer specimens and enable patient selection for targeted cancer therapies," added Meyerson.

The technology is already being explored at other institutions. "We have validated 454 Sequencing for medical sequencing on a gene target of interest," stated Robert Strausberg, Ph.D. Deputy Director and Vice President of Human Genomic Medicine at The J. Craig Venter Institute. "The method is not only very sensitive, but it is also quantitative and provides a digital display of gene variation within tumors. We have already identified a mutation missed by our previous sequencing approach," said Strausberg.

"The publication of this paper demonstrates the versatility of our system and its ability to enable medical research that has been considered impractical until now," stated co-author Michael Egholm, Ph.D., Vice President of Molecular Biology at 454 Life Sciences. "454 Sequencing can open new research opportunities through its low cost, high throughput, and superior sensitivity. The ability to sequence entire exons in a single read is unique to 454 Sequencing among the commercially available, next generation sequencing technologies. Ultimately, we hope our system will enable personalized medicine, such as identifying the early stages of drug resistance and facilitating a change in treatment that is tailored to a patient's unique genetic response," added Egholm.

[lottojan10]

heut wär wieder ein guter zeitpunkt einzusteigen 2,45 nehme ich mit, wenns klappt.

lotto

[lottojan10]

hat leider erst gestern zu 2,28 geklappt, zwar nur 500 st, aber wir sind auf alltimelow, bin mir sicher, daß es montag wieder rauf geht.

grüße

lotto

[bonDiacomova]

bon domingo lotto

empfehle Dir einen engen SL zu setzen

stichwort : Support Below : None

druecke Dir die daumen

BULLISH
Probability - Intermediate trend bullish, Unsustainable downtrend, may turn sideways.
Probability - 1 Day Price change extreme down, may pause/reverse
Probability - Extreme Oversold, odds definitely favor long trades.
Probability - Short term extreme pullback, expect pullback to pause/stop.
Confirmation - Extreme bearish 1 day moneyflow, on an strong-extreme pullback is considered bullish.


BEARISH
Confirmation - Strong bearish 3 day chart pattern with Mild 3 day distribution.

[lottojan10]

Antwort auf Beitrag Nr.: 22.968.551 von bonDiacomova am 23.07.06 11:33:04

ola bon dia,

so nun bin ich wohl der, der den günstigsten einstiegstermin bei crgn erwischt hat,

weil nach mir glaube ich keiner mehr gekauft oder verkauft hat.

wollen nur hoffen, daß jetzt endelich mal die 3 € bezwungen werden.

viele grüße nach malle.

ps.

hab übrigens auch noch ein wm spiel live sehen können, sitzt du ????


deutschland : portugal

geil wars

lotto

[lottojan10]

Antwort auf Beitrag Nr.: 23.010.857 von lottojan10 am 24.07.06 16:20:24

seh gerade, hat sich doch noch einer 58 st für 2,13 € einverleibt, was das wohl soll ????

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 23.010.857 von lottojan10 am 24.07.06 16:20:24

D : P

[lottojan10]

Antwort auf Beitrag Nr.: 23.057.739 von bonDiacomova am 26.07.06 07:02:59

verstehe nix bon dia, was meinst du ???

grüße

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 23.057.739 von bonDiacomova am 26.07.06 07:02:59

erklaerung

watt habe ich gesehen

wow - du hast

Deutschland : Portugal live erlebt

sehr schoen


saludos y suerte bd

[lottojan10]

Antwort auf Beitrag Nr.: 23.145.302 von bonDiacomova am 28.07.06 08:58:51

now i understand you,


ja war total geil, meine freundin hat sich auf blöd im internet nochmal beworben und bums lotto live in stuttgart und dann auch noch unsere jungs um platz 3, super stimmung, super spiel

welche spiele hast du gesehen, du warst in hh oder ?

was meinst du zu crgn, hab ich den richtigen einstieg getroffen ???

ich denke schon, die werden wieder bis 3,50 € laufen oder noch weiter hoch, habe ja noch aus 2000 um die 2000 € miese auszugleichen.

viele grüße nach malle, hab gehört das meer ist 28 ° warm ???

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 23.155.346 von lottojan10 am 28.07.06 19:36:00

moin loddo

da kommt doch freude auf
wofuer die frauen doch manchmal gu¡ud sind



mein persoenliches highlight argentinien : ivory
aber auch freiluft in HH - leinwaende und bei colegas
war echt ne suu¡uuper zeit

crgn sieht nicht schlecht aus

wasser 28/29 ... zu warm

bon fin de semana bd

[lottojan10]

Antwort auf Beitrag Nr.: 23.155.515 von bonDiacomova am 28.07.06 19:49:39

moin bon dia,

so mal wieder ein posting - bis 3,50 sind es jetzt nur noch 70 cent



heut gab es den größten umsatz in fra seid langem 12.500 st., wenn da mal nicht jemand was weiss, ich wars nicht, aber freue mich natürlich.

viele grüße
lotto

bei 3,20 überleg ich raus zu gehen, was meinst du bon dia???

[bonDiacomova]

moinmoin

wuerde auf jedenfall mit SL arbeiten
und in amiland schauen



sollte es sich um einen triple buttom ( 3 mal auf 2.75 )handeln
wird dieser normalerweise
durch kurzen ruecksetzer auf "ausbruchsniveau" bestaetigt
ergo nochmal zurueck naehe 3

saludos y suerte bd

[lottojan10]

sieht gut aus heute

lotto

[lottojan10]

so, wird wohl laufen bis 3,20 - 3,30 € und das sehr schnell, was meinst du bon dia ???


grüße nach malle

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 24.381.049 von lottojan10 am 03.10.06 17:13:53

moin loddo

schaut wirklich gut aus

gewinnmitnahmen nicht vergessen

schoen gruss zurueck

[lottojan10]

Antwort auf Beitrag Nr.: 24.413.232 von bonDiacomova am 05.10.06 08:04:13

heute geht die party ab, rechne mit mindestens 3, 20 €

ganz schön prall was ich hier ab lass, oder bon dia ??

grüße

lotto

[lottojan10]

Antwort auf Beitrag Nr.: 24.438.715 von lottojan10 am 06.10.06 13:00:22

tja, war wohl nix mir party -




na dann freuen wir uns eben auf montag

schönes wochenende

lotto

[lottojan10]

Antwort auf Beitrag Nr.: 24.451.944 von lottojan10 am 06.10.06 20:10:08

hop, hopp geh auf 4 in ami land

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 24.522.797 von lottojan10 am 09.10.06 19:29:00

BULLISH

None


BEARISH

Probability - Intermediate trend possibly bearish, Sideways trend near upper resistance.
Probability - Overbought, odds favor short trades.
Probability - Short term strong rally, rally may start to slow.
Probability - Mild bearish 3 day chart pattern with Good 3 day distribution.
Confirmation - Strong bearish 1 day moneyflow
Confirmation - at resistance

[lottojan10]

Antwort auf Beitrag Nr.: 24.549.560 von bonDiacomova am 11.10.06 05:51:54

tja, und nu ????

die 4 $ fallen nicht, denke gehe morgen raus.

malle viele grüße

lotto

[lottojan10]

Antwort auf Beitrag Nr.: 24.568.745 von lottojan10 am 11.10.06 21:43:43

ums mal anners auszudrücken:


was jetz los du olle scheiß axie, hoch oder runner




grüße

lotto

[lottojan10]

Antwort auf Beitrag Nr.: 24.682.943 von lottojan10 am 17.10.06 17:04:34

monolog :

heude hoch, hab diese axie noch nich verkauft



3,25 € sollten doch kommen oder bon dia ???

grüße

lotto

[cyberhai]

Hallo!

Bin bereits seit einigen Tagen hier investiert.

Schaut Euch mal die Major Holders und die Insider-Geschäfte an, die sehen positiv aus:

http://finance.yahoo.com/q/mh?s=CRGN
http://finance.yahoo.com/q/it?s=CRGN

Vor allem hat keiner der Insider, welche seit Jahren investiert sind, Aktien verkauft. Die wissen sicher, wieviel Potential noch da ist...

Gruß Cyberhai

[bonDiacomova]

Antwort auf Beitrag Nr.: 24.711.225 von lottojan10 am 18.10.06 21:52:28

bon dia

3,25 € sollten doch kommen oder...

ich denke ja - nur noch nich "morgen"



crgn ist beim 200 ma
ein ruecksetzer auf 3,40 $ ( 50 ma ) ist
genauso moeglich wie das ueberwinden der 4 $
sl : um die 3 $

saludos y suerte bd

RESISTANCE ABOVE
+3.4% at 3.91 ± 0.08, type single, strength 3
+10.6% at 4.18 ± 0.08, type double, strength 10
+15.9% at 4.38 ± 0.09, type double, strength 8
+24.6% at 4.71 ± 0.09, type single, strength 5

SUPPORT BELOW
-6.1% at 3.55 ± 0.07, type single, strength 5
-10.3% at 3.39 ± 0.07, type triple+, strength 10
-15.3% at 3.2 ± 0.06, type triple, strength 9
-19.8% at 3.03 ± 0.06, type double, strength 4
-24.3% at 2.86 ± 0.06, type single, strength 1



BULLISH
Confirmation - Strong bullish 3 day chart pattern.

BEARISH
Probability - Intermediate trend possibly bearish, Sideways trend near upper resistance.
Probability - 1 Day Price change extreme up, may pause/reverse
Probability - Overbought, odds favor short trades.
Confirmation - at resistance

[bonDiacomova]

[bonDiacomova]

Antwort auf Beitrag Nr.: 24.711.452 von cyberhai am 18.10.06 22:02:26

buenas hai

holdings etwas umfangreicher

http://holdings.nasdaq.com/asp/Institutional.asp?FormType=In…

[lottojan10]

ich liebe intraday frankfurt bei wo



grüße

lotto

[lottojan10]

Antwort auf Beitrag Nr.: 24.722.013 von lottojan10 am 19.10.06 15:32:55

war doch wieder schön heute.

grüße

lotto

[lottojan10]

Antwort auf Beitrag Nr.: 24.809.140 von lottojan10 am 23.10.06 22:23:58

moin bon dia,

wie siehts ct mäßig aus ?

grüße nach malle

lotto

[lottojan10]

Antwort auf Beitrag Nr.: 24.853.721 von lottojan10 am 25.10.06 21:14:25

ist das jetzt ein w oder ein m ????



hab leider immer noch keine ahnung davon.

grüße

lotto

[lottojan10]

Antwort auf Beitrag Nr.: 24.855.651 von lottojan10 am 25.10.06 22:28:05

und was passiert bei w und was passiert bei m



antwort bitte in das thal der ahnungslosen

danke

lotto

[bonDiacomova]

moin loddo

in F gilt es sowieso¡o nicht zu schauen
schau in amiland - # 163 - kein w kein m

die schnittpkte vom sma 15 - 30 - 50
anfang september deuteten auf anstieg
solange sich von oben nun nicht kreuzen
ist der aufwaerstrend in takt...

saludos y suerte bd




Overall Summary:
50%, Bullish
50%, Bearish

Upside:
85%, V. Good
Downside: 50%, Poor



BULLISH
Probability - Intermediate trend bullish, Uptrend.
Confirmation - Good bullish 1 day moneyflow


BEARISH
Probability - Mild bearish 3 day chart pattern with Strong 3 day distribution.


RESISTANCE ABOVE +3.5% at 3.87 ± 0.08, type double, strength 10
+11.8% at 4.18 ± 0.09, type double, strength 10
+17.1% at 4.38 ± 0.09, type double, strength 8
+25.9% at 4.71 ± 0.1, type single, strength 5


SUPPORT BELOW -5.1% at 3.55 ± 0.07, type single, strength 5
-9.4% at 3.39 ± 0.07, type triple+, strength 10
-14.4% at 3.2 ± 0.07, type triple, strength 9
-19.3% at 3.02 ± 0.06, type triple, strength 5
-23.5% at 2.86 ± 0.06, type single, strength 1

[bonDiacomova]

CuraGen Reports Third Quarter 2006 Results

http://biz.yahoo.com/prnews/061026/neth014.html?.v=76

[bonDiacomova]

loddo

wuerde nun "frech"

sl auf 3,88 $ setzen

[lottojan10]

Antwort auf Beitrag Nr.: 24.868.843 von bonDiacomova am 26.10.06 16:19:06

hoffe, du denkst nicht ich spinne habe aber eben meine unfähigkeit in bezug auf ct nochmal überprüft, folgendes ist dabei raus gekommen:


erster wiederstand jetzt bei 3,25 € der nächste dann bei ca 3,39 € und dann erst wieder bei ca 3,90 €.

was ist denn heute bei crgen los ???

haben die das gen zur penisverlängerug entdeckt ???



grüße

lotto

[lottojan10]

20.02.2006


tageshoch 5,90 €, weißt du ob zu 5,90€ was gehandelt wurde

volumen in fra war da 5790 st

grüße

lotto

[lottojan10]

20.02.2006


tageshoch 5,90 €, weißt du ob zu 5,90€ was gehandelt wurde

volumen in fra war da 5790 st

grüße

lotto

[lottojan10]

20.02.2006


tageshoch 5,90 €, weißt du ob zu 5,90€ was gehandelt wurde

volumen in fra war da 5790 st

grüße

lotto

[lottojan10]

20.02.2006

volumen 5790 st
tageshoch 5,90 € weißt du ob zu 5,90 € handel statt gefunden hat ?

grüße

lotto

[lottojan10]

tschuldigung aber grad hats hier mit der antwort gehakt

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 24.869.214 von lottojan10 am 26.10.06 16:31:59

20.02.2006



nee - aber schau doch bitte
nich immer nach F - schon gar nicht
wenns um charttechnik geht



solange sich die 3 linien
zwischen den BB`s
von oben nach unten nicht schneiden
ist der aufwaertstrend in takt

lege sl
goldene midde : naehe blaue linie
konservativ : braune
spekulativ : rote


saludos y suerte bd


p.s.
erster wiederstand
jetzt bei 3,25 €
der nächste dann bei ca 3,39 €
und dann erst wieder bei ca 3,90 €.

schau in $ und in amiland !!!

wiederstand - RESISTANCE ABOVE

+4.8% at 4.15 ± 0.08, type single, strength 2
+7.8% at 4.27 ± 0.09, type single, strength 5
+18.9% at 4.71 ± 0.09, type single, strength 5

unterstuetzung - SUPPORT BELOW

-5.1% at 3.76 ± 0.08, type triple+, strength 10 !!!
-10.6% at 3.54 ± 0.07, type single, strength 5
-14.4% at 3.39 ± 0.07, type triple+, strength 10 !!!
-19.9% at 3.17 ± 0.06, type triple, strength 9
-23.7% at 3.02 ± 0.06, type double, strength 3
-27.8% at 2.86 ± 0.06, type single, strength 1

[bonDiacomova]

CuraGen and TopoTarget Announce
Updated PXD101 Phase Ib Results
Presented at the EORTC-NCI-AACR Symposium
http://biz.yahoo.com/prnews/061110/nef004.html?.v=79


CuraGen and TopoTarget Announce
Initiation of NCI-Sponsored Phase II Trial of PXD101
for Ovarian Cancer
http://biz.yahoo.com/prnews/061114/netu023.html?.v=73


14-Nov-06
BWS Financial Initiated ---> Buy

[lottojan10]

@ bon dia

das läuft doch obersahne, hab ich recht, oder hab ich recht ???

grüße nach malle

und danke für deinen denkanstoß.

grüße

lotto

[lottojan10]

14.11.2006


Die Analysten von BWS Financial bewerten in ihrer Analyse vom Dienstag, 14. November 2006 die Aktie von CuraGen Corporation neu mit dem Rating "Buy". Das Kursziel für die Aktie liegt momentan bei 8 $.


13.12.2006


Die Analysten von Am Tech/ JSA Research bewerten in ihrer Analyse vom Mittwoch, 13. Dezember 2006 die Aktie von CuraGen Corporation neu mit dem Rating "Buy". Das Kursziel für die Aktie liegt momentan bei 8 $.


identischer wortlaut, schreiben die von einander ab, oder bringt wo die meldung so zu wort ????

grüße

lotto

[lottojan10]

keiner mehr da ?????

bon dia, was los ????

genießt du dein inselleben ???
gönn es dir ja.



grüße

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 26.181.000 von lottojan10 am 14.12.06 17:52:53

bondia loddo

bin schon im weihnachtsurlaub

wuensch Dir nen schoenes we

bon nadal y felice ano nuevo bd

[lottojan10]

wünsch ich dir auch bon dia



grüße

lotto

[lottojan10]

könnte kritisch werden, was meinst du bon dia ???

viele grüße

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 27.107.318 von lottojan10 am 22.01.07 11:58:36

moin loddo

siehe chart # 179

&

solange sich die 3 linien
zwischen den BB`s
von oben nach unten nicht schneiden
ist der aufwaertstrend in takt

&

Trade Quality:
Upside: 95%, Excellent
Downside: 30%, Poor

BULLISH
None
BEARISH
Probability - Intermediate trend bearish, Unsustainable uptrend, may turn sideways.
Confirmation - Strong bearish 3 day chart pattern.

RESISTANCE ABOVE
+6.7% at 4.79 ± 0.09, type single, strength 5
SUPPORT BELOW
-4.5% at 4.29 ± 0.08, type triple, strength 10
-7.6% at 4.15 ± 0.08, type double, strength 6
-12.5% at 3.93 ± 0.07, type single, strength 1
-16.3% at 3.76 ± 0.07, type double, strength 10
-24.5% at 3.39 ± 0.06, type triple, strength 10



bei unterschreiten eines schlusskurses von 4,20
wuerde ich geben

saludos y suerte bd

[bonDiacomova]

BULLISH
Probability - Short term typical pullback, pullback may start to slow.
Confirmation - Strong bullish 3 day chart pattern with Mild 3 day accumulation.
Confirmation - Strong bullish 1 day moneyflow
Confirmation - at support


BEARISH
Probability - Intermediate trend possibly bearish, Uptrend turned sideways, may continue or pullback.


RESISTANCE ABOVE
+9.9% at 4.79 ± 0.09, type single, strength 5


SUPPORT BELOW
-4.4% at 4.17 ± 0.08, type double, strength 6
-9.9% at 3.93 ± 0.07, type single, strength 1
-13.8% at 3.76 ± 0.07, type double, strength 10
-22.2% at 3.39 ± 0.06, type triple, strength 10
-27.3% at 3.17 ± 0.06, type triple, strength 10
-31.2% at 3 ± 0.06, type double, strength 4
-34.4% at 2.86 ± 0.05, type single, strength 1

[lottojan10]

Antwort auf Beitrag Nr.: 27.252.155 von bonDiacomova am 28.01.07 15:56:51

moin bon dia,

ziehe morgen die reißleine, wenn wir von 4,25 $ nicht weg kommen heut abend.

bin dann immer noch ganz gut gefahren.

halt mich bitte davon ab.



grüße

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 27.527.072 von lottojan10 am 08.02.07 21:17:40

moin

auf gar keinen fall
halte ich Dich davon ab

siehe chart # 179
solange sich die 3 linien
zwischen den BB`s
von oben nach unten nicht schneiden
ist der aufwaertstrend in takt

scheun tach bd

[bonDiacomova]

gw loddo

guder einstieg - guder ausstieg

guder trade

[lottojan10]

Antwort auf Beitrag Nr.: 27.915.741 von bonDiacomova am 23.02.07 07:22:44

danke bon dia,

auch wenns nur ne kleine position war liefs ganz gut.

mal sehen wann wir wieder rein können.



schönes we

grüße

lotto

[bonDiacomova]

08.02. zitat loddo :
ziehe morgen die reißleine, wenn wir von 4,25 $ nicht weg kommen...
...halt mich bitte davon ab.
zitat ende

09.02. bd :
auf gar keinen fall halte ich Dich davon ab

[bonDiacomova]

Antwort auf Beitrag Nr.: 27.942.924 von lottojan10 am 24.02.07 14:23:47

moin loddo

wollt gestern ko¡of`n ...
heut gehoer ich zu den do¡of`n

3.86 8.43%

[bonDiacomova]

27-Feb-07

BWS Financial Upgrade
from Buy to Strong Buy

[bonDiacomova]

4.12 15.73 %

[lottojan10]

Antwort auf Beitrag Nr.: 28.010.307 von bonDiacomova am 27.02.07 19:07:51

moin bon dia

wollen mal sehen ob es heute so weiter geht, wenn ja gehöre ich auch bald zu den doofen



grüße

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 28.022.005 von lottojan10 am 28.02.07 11:46:29

ich kann - oder will - es nicht glauben dass
es heude mit crgn weiter nach oben geht

[lottojan10]

Antwort auf Beitrag Nr.: 28.025.517 von bonDiacomova am 28.02.07 14:15:19

was ist denn in munich los 3,20 ??????

ist da was im busch ??

grüße

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 28.560.098 von lottojan10 am 29.03.07 13:21:02

WOW

CuraGen Announces Definitive Agreement to Sell
454 Life Sciences to Roche

http://biz.yahoo.com/prnews/070329/clth079.html?.v=70

Under the terms of the agreement 454 Life Sciences' shareholders will receive up to $154.9 million in cash of which Roche will pay $140 million in cash, and up to approximately $14.9 million will be received from the exercise of stock options issued and outstanding prior to the acquisition. Of the $140 million from Roche, $25 million will be placed in escrow for a period of 15 months. On a fully diluted basis, presuming exercise of all outstanding stock options, CuraGen expects to receive approximately $85 million before fees and expenses, of which approximately $14 million will be held in escrow.

[cyberhai]

Der Deal ist dem Markt zu wenig, die Aktie war erst ca. 5 % im Plus, jetzt 12 % Minus

[bonDiacomova]

Antwort auf Beitrag Nr.: 28.565.934 von cyberhai am 29.03.07 17:15:12

CuraGen Shares Drop on Deal

CuraGen Stock Falls on Sale of 454 Life Sciences to Roche Holdings


NEW YORK (AP)

Shares of CuragGen Corp. plunged Thursday after the biopharmaceutical company said it would sell its majority-owned subsidiary, 454 Life Sciences, to Roche Holdings AG for up to $154.9 million.

The stock lost 63 cents, or $16.4 percent, to $3.21 in afternoon trading on the Nasdaq Stock Market. Shares have traded between $2.73 and $5.01 over the last 52 weeks.

Piper Jaffray analyst Edward Tenthoff downgraded his rating on CuraGen's stock to "Market Perform" from "Outperform" and dropped his price target to $3.50 from $5 citing the deal and expected delays in a cancer treatment development program.

"Considering the majority of CuraGen's 2007 projected revenues were from 454 Life Sciences, we are dramatically reducing our revenue forecast to $11.9 million this year," he wrote in a note to investors. Tenthoff's previous revenue forecast was for $53.3 million.

CuraGen becomes a pure cancer drug discovery company after the deal, he noted. The company expects study results on its lead drug candidate velafermin in the third quarter.

The start of a second midstage study, however, for its belinostat in combination with Velcade to treat refractory multiple myleoma will likely be delayed by about six months. Tenthoff said that study was poorly designed and that a suboptimal dose of Velcade will likely make enrollment challenging.

[lottojan10]

Antwort auf Beitrag Nr.: 28.574.205 von bonDiacomova am 29.03.07 22:10:41

und ich hab noch das letzte kursziel von ich glaube 8 $ im ohr.

jetzt sind wir doch nicht die doofen bon dia.

puh glück gehabt.

ob ein einstieg heut sinn macht ?? kleiner rebound könnte kommen ??

scheint mir aber sehr gewagt, was meinst du bon dia ???

grüße

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 28.577.897 von lottojan10 am 30.03.07 09:34:09

moin loddo

ja - so¡O do¡of waren wir nicht

ich wuerde eroeffnung drueben abwarten...
koennte sein dass shorties verstaerkt decken heude...
ue 2 millionen shares short...

mak cap 174 mil $



tippe auf steigende kurse

scheunet we bd

[bonDiacomova]

Prev Close: 3.07
open 3.18

Bid: 3.17 x 7500
Ask: 3.19 x 400

[lottojan10]

Antwort auf Beitrag Nr.: 28.585.805 von bonDiacomova am 30.03.07 15:47:21

da hätt ich mir mehr erwartet.

grüße

lotto

[bonDiacomova]

frohe ostern loddo



BULLISH
Probability - Intermediate trend bullish, Unsustainable downtrend, may turn sideways.
Probability - Extreme Oversold, odds definitely favor long trades.
Confirmation - Strong bullish 3 day chart pattern with Extreme 3 day accumulation.
Confirmation - Good bullish 1 day moneyflow
Probability - Excessive Down trend (1 month), not sustainable, occurs only 10% of the time, expect trend to turn sideways or higher.
Probability - POSSIBLE breakout above 3.04, no resistance in area just above.

BEARISH
Probability - 1 Day Price change strong up, may pause

[lottojan10]

Antwort auf Beitrag Nr.: 28.710.922 von bonDiacomova am 08.04.07 08:32:04

upps, schon länger nicht mehr reingeschaut

jetzt noch frohe ostern zu wünschen is auch n bissel blöd, oder ?????



schönen tag bon dia

ps

finde deinen fc bayern thread und die bilder des tages übrigens spitze.

grüße

lotto

[lottojan10]

jetzt wieder einsteigen ?????

grüße

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 29.077.226 von lottojan10 am 30.04.07 20:11:10

moinmoin loddo

danke fuer die blumen

warum nicht
aber nur mit SL ---> SUPPORT BELOW None

Overall Summary:
80%, Bullish
20%, Bearish

Trade Quality:
Upside: 95%, Excellent
Downside: 30%, Poor

BULLISH
Probability - Intermediate trend bullish, Unsustainable downtrend, may turn sideways.
Probability - 1 Day Price change strong down, may pause
Probability - Extreme Oversold, odds definitely favor long trades.
Probability - Short term extreme pullback, expect pullback to pause/stop.
Confirmation - Extreme 3 day distribution, but when the stock is oversold this is considered bullish.
Confirmation - Extreme bearish 1 day moneyflow, on an strong-extreme pullback is considered bullish.
Probability - Strong Down trend (1 month), may start to turn sideways.

BEARISH
Confirmation - Strong bearish 3 day chart pattern.

RESISTANCE ABOVE
+15.5% at 2.98 ± 0.07, type double, strength 10
+22.5% at 3.16 ± 0.07, type single, strength 5
+29.8% at 3.35 ± 0.08, type single, strength 5
+42.6% at 3.68 ± 0.08, type double, strength 5
+50.4% at 3.88 ± 0.09, type triple+, strength 10
+62.4% at 4.19 ± 0.1, type triple+, strength 10
+68.2% at 4.34 ± 0.1, type triple, strength 10
+85.7% at 4.79 ± 0.11, type single, strength 5


SUPPORT BELOW None

[lottojan10]

Antwort auf Beitrag Nr.: 29.079.419 von bonDiacomova am 01.05.07 08:36:11

moin bon dia,

ich wart mal noch bissel.

bist du wieder investiert ???

grüße

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 29.126.567 von lottojan10 am 04.05.07 09:18:41

mahlzeit loddo

nein - i.m. nicht in crgn

da wir hier unter uns sind
erlaube ich mir Dich auf eine ag
aufmerksam zu machen ...

was die haben : " looks like a great discovery "
sagte mir einer der direktoren vorgestern beim fruehstueck

[lottojan10]

Antwort auf Beitrag Nr.: 29.132.800 von bonDiacomova am 04.05.07 15:15:49

moin bon dia,

danke für den hinweis, allein die wkn fehlt mir noch zu meinem glück.



oder wolltest du mir ne aufgabe stellen ??



grüße
nach malle von

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 29.147.387 von lottojan10 am 05.05.07 10:50:03

bon domingo loddo

nene

wennste ---> wml
oben links eingibst

WEALTH MINERALS LT

Letzter Kurs: 3,71 €
WKN: A0CADP
ISIN: CA9468851006

[lottojan10]

Antwort auf Beitrag Nr.: 29.163.590 von bonDiacomova am 06.05.07 07:47:40

danke bon dia.

grüße

lotto

[lottojan10]

Antwort auf Beitrag Nr.: 29.210.742 von lottojan10 am 08.05.07 13:23:17

moin bon dia,

hoffe du bist nicht auf bundesliga entzug



was meinst du wie gehts weiter bei crgn ???

soll der kleine lotto jetzt wieder einsteigen ???

grüße

nach malle

lotto

[bernie55]

ALLGEMEINE INFOS zur Zulassung neuer Arzneien


22.06.2007 - 09:28 Uhr

FTD: Das kann ja heiter werden

Die Zulassung neuer Arzneien ist für die Pharmabranche längst keine Kleinigkeit mehr. Regelmäßig lassen die Behörden Hoffnungsträger durchfallen und Börsenträume platzen. Künftig kommt es noch dicker.


Sanofi-Aventis ist fassungslos über die Ablehnung seiner Diätpille Acomplia bei der US-Behörde FDA. Begründung: psychische Nebenwirkungen.

GlaxoSmithKline fürchtet das Aus für das umsatzstarke Diabetesmittel Avandia. Risiko: Herzinfarkt.

Das neue Krebsmittel Vectibix vom weltgrößten Biotechkonzern Amgen findet nicht den Zuspruch der Kontrolleure bei der EU-Behörde Emea. Erklärung: Wirksamkeit zweifelhaft.

Drei Beispiele aus der jüngsten Vergangenheit - eine gemeinsame Wirkung: Aufruhr an der Börse. Die Aktienkurse der betreffenden Konzerne sackten nacheinander auf ein Zweijahrestief. Allen Beteiligten, den Managern, Analysten und Kontrolleuren steckt noch der Skandal um das Schmerzmittel Vioxx in den Knochen. Die Folge für den Hersteller Merck & Co. sowie die Branche waren Tausende Schadensersatzklagen, Imagekrisen und Milliardenverluste. Das mahnte zur Vorsicht. Im Jahr drei nach Vioxx zieht die Politik auf beiden Seiten des Atlantiks die Zügel nun noch fester an.

So feilten am Donnerstag in Washington US-Senatoren an letzten Details für ein Gesetz, das der FDA mehr Einfluss und Geld für zusätzliche Sicherheitskontrollen von Medikamenten gibt. Dazu zahlt die Industrie an die FDA Gebühren von rund 400 Mio. $ jährlich, weitere 225 Mio. $ bringt sie in den kommenden fünf Jahren für die FDA-Observierung von Neueinführungen auf. "Die Nation hat aus den Sicherheitsproblemen mit dem Diabetesmedikament Avandia gelernt", sagte der Vorsitzende des Kongressausschusses, John Dingell, vor wenigen Tagen. Zudem können Verstöße gegen Marketing- und Sicherheitsauflagen mit bis zu 100 Mio. $
Strafe geahndet werden.

Und auch die Emea kann nun härter durchgreifen. Die EU-Kommission hat am 15. Juni eine Verordnung in Kraft gesetzt die Verstöße gegen Emea-Regeln mit hohen Geldbußen ahndet - etwa, wenn Firmen Vorgaben ihrer Arzneimittelzulassungen nicht einhalten, Informationen zur Risikobewertung ihrer Produkte zurückhalten oder deren Nebenwirkungen gar nicht oder erst sehr spät melden.

"Sehr harte Sanktionen"

Die Höchstgrenze der Geldbußen liegt bei fünf Prozent des Jahresumsatzes des betroffenen Zulassungsinhabers. Zulassungsinhaber kann auch eine Konzerntochter sein. "Das dürfte zu ungerechten Bestrafungen führen", sagte Unternehmensanwalt Uwe Fröhlich vom Pharmakonzern Baxter. "Zufälligerweise oder sogar absichtlich kann ein besonders umsatzstarker oder umsatzschwacher Teil eines Konzerns Inhaber der Zulassung sein. Ein Schlupfloch könnten auch Vermarktungspartnerschaften unabhängiger Unternehmen bieten, von denen nur eines die Zulassung hält." Gerechter sei es, die Buße am EU-weiten Umsatz der Arznei festzumachen. "Das sind alles in allem sehr harte Sanktionen", sagt Anwalt Jörg Schickert von der Kanzlei Lovells in München. Er findet manches an der Verordnung unausgereift. "Es gibt noch Schwachstellen, darunter die Frage, wie die Abgrenzung zwischen einzelstaatlichen Strafmaßnahmen und EU-weiten Sanktionen geregelt werden soll."

Das für Zulassungen zuständige Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) habe in der jüngeren Vergangenheit einige Straf- und Bußgeldverfahren eingeleitet, mit unterschiedlichem Ausgang entsprechend der Beweislage, heißt es auf Anfrage. "Ob es in Zukunft wichtiger sein wird, derartige Instrumentarien zur Verfügung zu haben, lässt sich nur schwer einschätzen", so das BfArM. Die im Arzneimittelgesetz für Ordnungswidrigkeiten vorgesehenen Bußgelder von maximal 25.000 Euro seien vergleichsweise gering.

Die Verordnung (EG) 658/2007 zur Auferlegung von Geldbußen durch die Kommission ist ein neuartiges Sanktionsmittel, das es für von der Emea zugelassene Arzneimittel bislang noch nicht gab. "Die Industrie sollte schnellstmöglich alle Schwachstellen abklopfen und Verfahren aufsetzen, die zukünftig Verstöße vermeiden. Dies sollte auch dokumentiert werden", sagte der Anwalt Schickert.

Emea-Chef Thomas Lönngren zumindest will nie mehr einen Tag wie den 30. September 2004 erleben: Weder der Vioxx-Hersteller Merck & Co. noch die FDA-Kollegen hatten ihn frühzeitig über den geplanten Rückruf der Schmerzpille informiert. Die Börse wusste früher Bescheid als er. "Wir wollen von Konzernen so schnell wie möglich informiert werden", sagte er.



Autor/Autoren: Peter Kuchenbuch

http://www.finanztreff.de/ftreff/news.htm?sektion=topthemen&…

[bonDiacomova]

Antwort auf Beitrag Nr.: 30.141.660 von lottojan10 am 22.06.07 09:28:13

bon domingo lotto

ist noch "auszuhalten"
hier war ja gerade erst pokal endspiel

crgn :


downtrend noch intakt
klar besteht die moeglichkeit
dass sie hier mal wieder dreht...
jede erholung ist imho begrenzt
durch den verkauf - #202
kauf Dir lieber wml

[lottojan10]

Antwort auf Beitrag Nr.: 30.268.457 von bonDiacomova am 24.06.07 09:22:34

moin bon dia,

hab mal die finger von crgn gelassen.

bin aber jeder zeit zu ner schandtat bereit

wenn es denn aussichtsreich erscheint.

wml ist auf meiner wl. sind die gerade günstig ????

grüße

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 30.656.494 von lottojan10 am 12.07.07 16:52:21

moinmoin loddo

daste z.Z. die finger von crgn
gelassen hast finde ich gu¡ut

wml - ist ein invest wert; ich weiss ja
nicht ob hier schon boden ist aber wir
sehen hier imho dies j. noch die 5
oder me¡er ...

[lottojan10]

Antwort auf Beitrag Nr.: 30.663.872 von bonDiacomova am 13.07.07 05:27:47

moin bon dia,

jetzt sollte aber doch langsam mal wieder n upmove kommen:



grüße

lotto

[lottojan10]

Antwort auf Beitrag Nr.: 30.740.161 von lottojan10 am 18.07.07 09:44:36

hab son komisches gefühl in meinem kugelbauch, als ob da in den nächsten tagen was geht.

kann mich natürlich auch täuschen.

mal sehn.
grüße

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 30.745.891 von lottojan10 am 18.07.07 16:19:48

moinmoin loddo

nach der stochi koennte es gut sein
aber wie gesagt - sehr begrenzt

scheun tach

[lottojan10]

moin zusammen,

diese woche noch penny stock ????



grüße

lotto

[bonDiacomova]

moin - nu koennte !
ne tradingchance gekommen sein


BULLISH
Probability - Intermediate trend bullish, Unsustainable downtrend, may turn sideways.
Probability - Extreme Oversold, odds definitely favor long trades.
Probability - Short term extreme pullback, expect pullback to pause/stop.
Confirmation - Extreme 3 day distribution, but when the stock is oversold this is considered bullish.
Confirmation - Extreme bearish 1 day moneyflow, on an strong-extreme pullback is considered bullish.
Probability - Strong Down trend (1 month), may start to turn sideways.
Confirmation - at support


BEARISH
Confirmation - Strong bearish 3 day chart pattern.

[lottojan10]

Antwort auf Beitrag Nr.: 30.937.733 von bonDiacomova am 30.07.07 15:50:49

moin bon dia,

nun penny stock, hab ich nicht mit gerechnet.

prognose von lotto:

um den euro pendelnde bewegungen mit 10% ausschlägen nach norden und süden.

kursziel 90 tage 85 cent.

bin zu feige jetzt schon rein zugehen, an meiner prognose muss ich mich messen lassen

was ist bei wml los ? gestern und heute schön grün.



grüße

nach malle

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 30.954.446 von lottojan10 am 31.07.07 17:59:18

Bid: 1.20 x 148500

[bonDiacomova]

vk 1.30
selbst nit dieser schwei.. aktie
kann man geld machen

[lottojan10]

Antwort auf Beitrag Nr.: 31.012.208 von bonDiacomova am 03.08.07 20:50:21

glückwunsch bon dia



grüße

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 31.055.250 von lottojan10 am 06.08.07 19:38:50

moin loddo

danke - es ist/war zwar nicht schlecht
aber nicht der rede wert
da mir die "richtigen" summen
leider nicht zur verfuegung standen...
bin me¡er am kaufen bei wml.

scheun tach

[lottojan10]

Antwort auf Beitrag Nr.: 31.058.842 von bonDiacomova am 07.08.07 05:31:37

moin bon dia,

bei wml läufts aber gar nicht so dolle, außgenommen der heutige tag.

weißt du mehr ???????



alter insulaner



ps

dein fcb thread ist im übrigen spitze, gute leute an bord, muß dich unbedingt noch einholen du spitzenreiter


6 punkte, - das wird schwer

grüße ins hoffentlich sonnige ei - land

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 31.242.186 von lottojan10 am 21.08.07 16:35:59

argentinien hat in allen zustaendigen stellen
die eroeffnung alter und neuer uran minen beschlossen...
imho "solltest" Du kaufen

---
die saison ist noch lang - da sind
6 punkte vorsprung doch nix
---

jo - is sonning - 29 grad gestern
obwohl es gestern morgen geregnet hat
1. mal seit april - 38 liter auf`m qm

scheun tach bd

[bonDiacomova]

curagen scheint seitwaertstrend zu bilden
denke bollinger werden noch enger...



bei wml haben gestern "alle" notwendigen herren unterschrieben
strong watch mein lieber
saludos y suerte y scheunet we

[bonDiacomova]

• CURAGEN CORP Files SEC form 8-K, Other Events
EDGAR Online (Thu 8:21am)
• CuraGen Drug Fails Midstage Study
AP (Thu 7:41am)
• CuraGen to stop development of oral mucositis drug candidate
at Reuters (Thu 7:29am)
• InPlay: CuraGen announces top-line phase ii results on Velafermin; demonstrated that velafermin was safe and well-tolerated but did not meet its primary endpoint
Briefing.com (Thu 7:01am)
• CuraGen Announces Top-Line Phase II Results on Velafermin
PR Newswire (Thu 7:00am)
http://finance.yahoo.com/q?s=CRGN

noch fragen

[lottojan10]

Antwort auf Beitrag Nr.: 31.940.439 von bonDiacomova am 11.10.07 15:49:13

grüße

lotto

[lottojan10]

Antwort auf Beitrag Nr.: 31.960.504 von lottojan10 am 12.10.07 18:25:13

gibt´s news ??????

grüße

lotto

[bonDiacomova]

Antwort auf Beitrag Nr.: 32.197.420 von lottojan10 am 30.10.07 00:07:10

bon dia loddo

noe - gestern nicht
scheinbar ein groesserer kaeufer

[blepat]

Totgesagte leben länger!
Curagen hat 2007 wohl eine der schlechtesten Performances auf dem Nasdaq hingelegt.
Jetzt steht sogar das Listing auf dem Spiel.
Aber dennoch.

Tolle Pipeline.

Partnerschaft mit Topo.

über 100 Mio cash.

Vorzeitige Tilgung der Schulden läuft.

DAS STINKT NACH ÜBERNAHME.

Ein Übernahmepreis von 2$ würde mir reichen.